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Chieh Tseng, Ph.D.
Advisory Professor: Mikhail G.Kolonin, Ph.D.

Obesity increases cancer risk and progression as shown by epidemiologic studies.
However, the underlying pathophysiology remained unclear. Adipose stromal cells (ASC)
are adipose tissue-derived mesenchymal progenitors, abundant in white adipose tissue
(WAT). In this study, we show that the ASC pool is expanded in obesity and is associated
with promoted tumor growth. Next, by using a chimeric GFP-RFP bone marrow
transplant model, we observed higher tumor infiltrating cells with ASC phenotype in
obese mice compared to lean. Consistently, systemic circulating ASC frequency is six
fold higher in tumor-bearing obese mice compared to lean. The tumor infiltrating cells
with ASC phenotype are found to be perivascular, suggesting them being incorporated
into vessels as pericytes to support tumor vasculature. We obtained evidence that ASC is
mobilized in response to obesity and cancer, however, the mechanisms regulating ASC
trafficking are poorly defined. We previously reported that the binding of the
matricellular protein SPARC to β1 integrin on ASC surface induces their motility. Here,
we demonstrate that absence of SPARC diminishes ASC capacity to mobilize. As
adiposity correlates with circulating SPARC and is the major producer of it, we evaluate
iii

SPARC level in distinct adipose depots and identify two SPARC proteolytic isoforms: CSPARC (lacking the N-terminus) and N-SPARC (lacking the C-terminus), generated in
the mesenteric white adipose tissue of obese mice. Both isoforms exhibit distinct 1
integrin binding capacity. C-SPARC binds to β1 integrin on ASC, while N-SPARC fails
to, but shows to be a potent extracellular matrix (ECM) / integrin interaction blocker and
these events are associated with integrin-dependent FAK-ERK signaling and integrinindependent ILK-Akt signaling. We show that both isoforms induce ASC de-adhesion
and, acting through different mechanisms, have additive effect in promoting ASC
migration.

iv

Table of Contents

Abstract …………………………………………………………………………….. iii
Table of contents………………………………………………………………….… v
List of Tables…………………………………………………………………………vi
List of Figures………………………………………………………………………...vi
Chapter 1: Introduction………………………………………………………………. 1
Chapter 2: Literature Review………………………………………………………… 4
Chapter 3: Methods and Material…………………………………………………….. 37
Chapter 4: Results…………………………………………………………………….. 47
Chapter 5: Discussion and Conclusion……………………………………………….. 88
Chapter 6: Future direction…………………………………………………………… 95
Bibliography………………………………………………………………………….. 100
Vita…………………………………………………………………………………… 123

v

List of Tables
Table 1: ASC and MSC immunophenotype………………………………………12

List of Figures
Figure 1-1. Cellular components of white adipose tissue………………………… 9
Figure1-2. Proposed functions of ASC in adipose tissue remodeling and tumor
progression ……………………………………………………………………….. 16
Figure1-3. Functional domains of SPARC ……………………………………….. 22
Figure 4-1. ASC expansion promotes tumor growth …………………………….. 52
Figure 4-2. Pericyte recruitment in obesity and tumor vascularization…………… 56
Figure 4-3. SPARC promotes ASC mobilization and migration………………….. 60
Figure 4-4. SPARC induce ASC deadhesion is linked with 1 integrin signaling... 64
Figure 4-5. Obesity-induced SPARC isoforms in MS WAT……………………… 70
Figure 4-6. C-SPARC but not N-SPARC binds to ASC………………………….. 75
Figure 4-7. N-SPARC is a potent extracellular matrix (ECM) binder and integrin... 78

interaction blocker
Figure 4-8. Both C-SPARC and N-SPARC modulate 1 integrin signaling……… 81
Figure 4-9. Both C-SPARC and N-SPARC induce ASC deadhesion and cooperate in
triggering ASC migration………………………………………………………….. 84
Figure 4-9. Proposed model……………………………………………………….. 86
Figure 6-1. Absence of host SPARC is associated with tumor growth deficiency.. 98
Figure 6-2. Decreased vasculature in tumors grown in SPARC-/- mice…………… 99

vi

Chapter 1
Introduction
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OBESITY
Obesity, a term to describe excessive accumulation of white adipose tissue (WAT)
is defined as body mass index (BMI=weight/height2) of ≥30 kg/m2 (Renehan et al., 2008).
The association of obesity and disease has been long recognized, as Greek physician
Hippocrates wrote “Corpulence is not only a disease itself, but the harbinger of others”
(Haslam and James, 2005). Indeed, subsequent epidemiological studies demonstrated that
obesity increases the risk and mortality rate and is associated with multiple diseases
including metabolic disorders, cardiovascular diseases and several cancers (colorectal,
esophageal, kidney and pancreatic cancer) (Basen-Engquist and Chang, 2011; Renehan et
al., 2008).
Report by World Health Organization (WHO) showed that the worldwide obesity rate has
doubled since 1980 and it is estimated that at least 6 million adults worldwide were obese
in 2014. Unfortunately, the obesity problem extends to children as well. It is reported that
at least 42 million children below the age of five are overweight. This predisposes the child
to obesity in adulthood and causes them to be more susceptible to metabolic disorders. The
alarming rise in obesity incidence accompany its negative health impact is appalling and
has highlighted the importance of understanding obesity pathophysiology.
The causes of obesity are multifactorial and have been associated with complex interaction
between genetic and environmental components (Renehan et al., 2015). The genetic
influence on obesity is observed in twin studies showing a stronger concordance for fat
mass among identical twins (70–90%) compared to fraternal twins (35–45%) (Gibbons,
2008; Silventoinen et al., 2010). In addition, genetic aberrations including single gene
mutations in melanocortin-4 receptor (MC4R), pro-opiomelanocortin (POMC), leptin and
2

leptin receptor or single-nucleotide polymorphisms also attribute individuals to higher
obesity susceptibility (Barsh et al., 2000). These studies have provided compelling
evidence on the importance of genetic heritability on obesity (Stunkard et al., 1986). The
other major attributors to obesity includes changes in human behavior of adapting to a
more sedentary lifestyle, aging, increased accessibility to and intake of high caloric foods
parallel the rising prevalence of obesity worldwide (Kopelman, 2000). In sum, obesity
results from a chronic surplus in energy which tips over the immune balance of adipose
tissue. This drives the adipose tissue microenvironment to become pro-inflammatory and
remain in the state of chronic inflammation (Cinti, 2005; Kopelman, 2000). To elucidate
the pathophysiology of obesity and its clinical manifestations, it is fundamental to have a
comprehensive understanding in the role of adipose tissue and its link in pathology.
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Chapter 2
Literature Review
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Obesity and Inflammation
Obesity, characterized by a prolonged state of low-grade inflammation, has been
linked by mounting evidence to increase cancer risks and is involved in the development of
metabolic disorders including type II diabetes, dyslipidemia and cardiovascular diseases
(Muoio and Newgard, 2008; Ouchi et al., 2011).
Inflammation is a biological response triggered by pathological events such as tissue
injuries, infection and toxic stimuli (Medzhitov, 2008). Short-term (acute) inflammation is
largely believed to be beneficial that facilitates tissue repair and protects against infection.
However, when inflammation is prolonged as observed in obesity, detrimental effects
result as chemical mediators and structural dynamics of adipose tissue changes (Sun et al.,
2011).
Generally, the adipose tissue (AT) of a healthy individual predominantly resides with
regulatory immune cells such as type 2 lymphocytes and eosinophils (Sun et al., 2011).
The cytokines secreted by regulatory immune cells include interleukin (IL)-10, IL-4 and
IL-13, which promote adipose tissue-residing macrophages (ATM) to retain their antiinflammatory M2 state (Makki et al., 2013). However, in obesity, the rapid expansion of
adipose tissue associated with elevated expression of stress makers on the adipocyte cell
surface, increased cellular turnover rate and upregulation of chemotactic factors that have
been shown to increase pro-inflammatory M1 macrophages (Wellen and Hotamisligil,
2003). The heightened production of IFN-γ by pro-inflammatory immune cells (e.g. NK
cells and CD8+ T cells), drives ATM to polarize and switch to pro-inflammatory M1 state.
In addition, elevated cell death and increased expression levels of monocyte chemotactic
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protein (MCP)-1, -1, -2, -3 and RANTES in adipose tissue also increase macrophage
infiltration. Previous studies reported an increase from 10-15% of ATM in lean visceral
adipose tissue to 50% ATMs in obese mice (Schipper et al., 2012; Sun et al., 2011). These
pro-inflammatory macrophages increase collagen deposition and induce adipose tissue
fibrosis, which leads to further exacerbation of adipose tissue inflammation as it limits
proper adipose tissue expansion and deregulates adipocyte function. Macrophages
infiltrating WAT in obesity are the major secretors of IL -6 and tumor necrosis factor-
(TNF-), which lead to insulin resistance by blocking insulin signaling (Hotamisligil et al.,
1994) and reduce glucose transporter GLUT4 expression in adipocytes (Lumeng et al.,
2007). Aside from macrophages, adipokines from adipocytes and other adipose-residing
cells are also associated with poor clinical manifestations of obesity.
Insulin resistance and glucose intolerance have been associated with aberrations in
adipokines: leptin and TNF-α that regulate inflammatory responses and glucose
metabolism through modulating activities of JNK-1 and IKKβ pathway (de Luca and
Olefsky, 2008), while resistin promotes insulin resistance by modulating the activity of the
insulin signaling inhibitor: suppressor of cytokine signalling 3 (SOCS3) (Ouchi et al.,
2011). Adipokines with trophic effects including insulin-like growth factors (IGFs),
epidermal growth factor (EGF), and transforming growth factor-beta (TGF-β) confer
malignant cells with advantages in survival and proliferation. Upregulated TGF-β and IL-6
in obesity promote tumor angiogenesis by stimulating growth factors activity such as
hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and
fibroblast growth factors (FGF-1 and FGF-2) (Calle and Kaaks, 2004; Renehan et al.,
2008).
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ADIPOSE STROMAL CELLS

Adipose Tissue Function and Composition
The AT consists of two different type of adipose tissue, namely the energy-storing
WAT and energy-dissipating brown adipose tissue (BAT). WAT and BAT exhibit distinct
functionality. BAT is characterized by high level of mitochondria uncoupling protein 1
(UCP1), best known to produce heat by non-shivering thermogenesis through uncoupling
the oxidative respiration from adenosine triphosphate production (Cinti, 2011; Virtanen et
al., 2009). During cold acclimation, the activation of -adrenergic receptor in brown
adipocyte cell membranes leads to free fatty acid (FFA) production (Ouellet et al., 2012).
The high level of FFA activates UCP-1 to increase proton leakage and heat dissipation.
Morphologically, brown adipocyte contains smaller, multilocular lipid droplets whereas
WAT is characterized by large unilocular lipid droplets (Cinti, 2011; Hassan et al., 2012).
Structurally, the WAT takes the form of loose connective tissue that is commonly found
attached to other organs. WAT is present in multiple discrete sites in the body. The bestdefined WAT depots in human are subcutaneous (SC) WAT and intra-abdominal WAT.
The intra-abdominal WAT is also known as visceral or intraperitoneal (i.p.). The visceral
adipose depots include omental WAT (associated with stomach), mesenteric WAT
(associated with intestine) and peripheric (surrounding the kidney). Adipocytes can be
found embedded in with other tissues such as skeletal muscles and lymph nodes) (Bjorndal
et al., 2011; Lee et al., 2013). Given its organization and distribution, WAT has been
recognized as a thermal insulator (providing heat and protecting organ against mechanical
stress) and energy storing depot of the body (Cinti, 2012). The unique feature of WAT to
uptake and store excessive energy as triacylglycerols and release of the lipids in times of
7

need, helps an animal survival when food is scarce. A more comprehensive evaluation of
WAT function in recent years has found WAT to be an active endocrine organ that
regulates metabolism, inflammation and reproduction (Trayhurn and Wood, 2005).
The lipid-laden adipocyte is the major component of AT that constitutes about 50% of the
AT cellular contents while the other half are immune cells, fibroblast, endothelial cells and
progenitor cells (adipose stromal cells) ( Fig. 1-1) (Tsuji et al., 2014). To study the highly
heterogeneous cellular content of AT, physical dissociation (mincing) along with
enzymatic collagenase digestion, followed by a defined immunophenotype of the cell
surface markers can be employed to isolate specific cell population of interest.
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Figure1-1 Cellular components of white adipose tissue. The white adipose tissue
composed of mainly the lipid-laden adipocyte (50%) and stromal vascular fraction (cell
pellet) containing haematopiotic cells, preadipocyte, endothelial cells and progenitor cells
(adipose stromal cells). The cellular components within WAT can be separated by
enzymatic collagenase digestion.
Figure obtained with permission of Springer from book chapter “Tseng C & Kolonin MG. Adipose TissueDerived Progenitor Cells and Cancer. In: Angiogenesis in Adipose Tissue. Springer, New York, 2013,
pp321-337

9

Adipose stromal cells
The adipose stromal cells (ASC) are a multipotent cell population residing in the
perivascular niche of AT (Kolonin et al., 2012). ASC share traits previously reported in
bone marrow-derived mesenchymal stem cell (MSC), documented as plastic-adhering
fibroblastoid colony-forming units (CFU-F). ASC display high proliferative capacity and
are able to differentiate into cells of mesodermal lineages: fat, bone, cartilage, muscle and
non-mesodermal origin: neuron-like cells (Gimble et al., 2011). Previous studies revealed
activation of ASC under ischemic conditions, as well as them participating in tissue repair
by supporting angiogenesis and modulating immune response (Bagno et al., 2012; Puissant
et al., 2005). Given the ease of isolation and abundance of ASC in adipose tissue, ASC has
emerged as a promising source of progenitor cells for regenerative medicine (Gimble et al.,
2007). ASC can be isolated from resected AT by enzymatic collagenase digestion to obtain
the non-lipid-laden cell pellet named the stromal vascular fraction (SVF).
Similar to progenitor cells from different sources, the heterogeneity and sensitivity of
surface marker expression to manipulation (cell isolation protocol and culture conditions)
of ASC have rendered it a challenge to accurately assign a specific immunophenotypic
signature to ASC. Thus, at present, no definitive surface markers are given to the ASC cell
population. To characterize ASC, the International Society for Cellular Therapy (ISCT)
and International Federation for Adipose Therapeutics and Science (IFATS) have
recommended basing the definition of ASC on their multilineage potential, plastic adherent
properties and immunophenotype (Bourin et al., 2013).
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The surface marker expression on ASC has been characterized by several groups (Bourin
et al., 2013; Maumus et al., 2011; Zimmerlin et al., 2010) using flow cytometry. As ASC
and MSC have overlapping traits and functions, initially, it was postulated that the two cell
populations may be identical. However, more recent studies showed a different propensity
of ASC and MSC to differentiate into distinct cell lineages (Huang et al., 2005; Im et al.,
2005) and differences in cell surface marker profile (described in Table 1). It is shown that
CD36 and CD34 are expressed on ASC but not on MSC (Pachon-Pena et al., 2011;
Sengenes et al., 2005).
Our group and others have isolated plastic-adhering fibroblastoid cells that are negative for
leukocyte and endothelial cell surface markers: CD45 and CD31, respectively and positive
for the progenitor cell marker CD34 (Traktuev et al., 2008; Zhang et al., 2009). This CD45
negative CD31 negative CD34 positive (CD45-CD31- CD34+) immunophenotype has
been faithful for isolation of cells validated to be capable of differentiating into
chondrocytes, adipocytes and osteoblasts in vitro. Recently, by combinatorial phage
display approaches, our group has identified 51 integrin and a new decorin derivative to
be expressed on ASC with progenitor capacity (Nie et al., 2008) (Daquinag et al., 2011).
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Table 1: ASC and MSC immunophenotype. The cell surface markers expression on
freshly isolated ASC or MSC, determined by flow cytometry analysis.
(Adapted from Minteer, D.M., Marra, K.G., and Rubin, J.P. (2015). Adipose stem cells: biology, safety,
regulation, and regenerative potential. Clin Plast Surg 43,169-179 and Bourin, P., Bunnell, B.A., Casteilla, L.,
Dominici, M., Katz, A.J., March, K.L., Redl, H., Rubin, J.P., Yoshimura, K., and Gimble, J.M. (2013).
Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissuederived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and
Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy 15, 641-648. )

Multiple studies demonstrated beneficial effects of ASC, participating in tissue repair by
increasing angiogenesis, immunosuppression (Puissant et al., 2005), resolving scar tissue
formation and secretion of growth factors. Transplantation of ASC in hindlimb ischemic
mice showed an increase in angiogenesis associated with elevated angiogenic growth
factor production. Human and rat ASC engraftment in myocardial infarction models have
shown to significantly improve cardiac function and diminish scar area in the injured
region (Bagno et al., 2012; Cai et al., 2009). Similar to MSC, ASC do not express major
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histocompatibility complex (MHC) class II (Tse et al., 2003), are immunoprivileged and
inhibit lymphocyte activation and proliferation in response to mitogens (Puissant et al.,
2005). In additional, ASC also modulate immune response by attenuating macrophage
infiltration (Lin et al., 2013). Importantly, as the major component of SVF, the ASC are
crucial in adipose tissue expansion serving as adipocytes precursor and to support blood
vessel development (Fig.1-2). Angiogenesis relies on coordinated assembly of perivascular
matrix, endothelial cells (EC) and pericytes (Song et al., 2005; von Tell et al., 2006). The
formation of mature blood vessel requires close association of pericytes to EC (Gerhardt
and Semb, 2008). The absence of pericyte coverage in pericytes-depleted mouse models
(Song et al., 2005) or impaired pericytes recruitment by antagonist results in increased
vessel permeabilization and leakage (Cooke et al., 2012). The perivascular location of ASC
and association with EC suggested them as pericytes/adventitial cells (Tang et al., 2008;
Traktuev et al., 2008). It is believed that the pro-angiogenic capacity of ASC is acted upon
through its paracrine effect, by secretion of angiogenic factors that modulate EC growth,
survival and differentiation (Gerhardt and Semb, 2008; von Tell et al., 2006)
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Adipose stromal progenitor cells and their potential pathological
functions
The inherent properties of ASC have drawn great clinical interest, recognizing the
potential of these cells in tissue repair coupled with immunosuppressive ability, therefore
ASC, offer great therapeutic promise for a large number of immune and degenerative
diseases. However, like a double-edge sword, the pro-angiogenic, cell death evading and
immunomodulatory properties of ASC are implicated in pathological processes as well.
Tumors may exploit these features to facilitate cancer progression, raising significant
safety concerns for clinical applications (Bertolini et al., 2015; Zhang et al., 2009).
Similar to tissue growth, tumor progression relies on establishment of functional
microenvironment and recruitment of cells to form new vasculatures, to support its
expansion. Tumor vasculatures are distinct from normal tissues, as they are characterized
by a chaotic mixture of irregular vessels that are often tortuous, functional flawed and
leaky. The abnormalities in cellular arrangement and perivascular matrix result in
compromised perfusion with inefficient nutrient delivery and waste clearance (Nagy and
Dvorak, 2012). Multiple studies showed that ASC promote neovascularization, and that
circulating ASC numbers increase in cancer (Bellows et al., 2011) (Kidd et al., 2012;
Klopp et al., 2012; Zhang et al., 2009) In tumors, ASC are found located in the
perivascular region, contributing to tumor vasculature integrity. It has been proposed that
the secretomes from ASC contain growth factors such as HGF, VEGF and fibroblast
growth factor that enhance EC survival, growth and sprouting in tumors.
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In addition to their vasculogenic role, ASC contribute to ECM remodeling and enhance
ECM stiffness (Chandler et al., 2012). ASC along with adipocytes and other SVF cells
modulate the production of ECM structural proteins including collagens and fibronectin
(Kolonin et al., 2012; Mariman and Wang, 2010). In obesity, the ASC pool is expanded.
Concomitantly, changes in ECM structural components and upregulation of inflammatory
genes (Henegar et al., 2008; Mariman and Wang, 2010) increase ECM rigidity. The ECM
stiffness is crucial in dictating cell behavior (Mariman and Wang, 2010), showing
increased proliferation and invasiveness of malignant cells on rigid ECM (Alexander et al.,
2008; Ulrich et al., 2009).
ASC have been proposed to serve as cancer-associated fibroblasts (CAF) (Kidd et al., 2012;
Klopp et al., 2012; Kolonin et al., 2012; Zhang et al., 2009 ). CAF are fibroblast-like cells
that facilitate tumor progression through conferring oncogenic signals and structural
support to malignant cells (Karnoub et al., 2007; Olumi et al., 1999). Furthermore, CAF
increase malignant cell survival through activating nuclear factor-B (NF-B)-regulated
anti-apoptotic signaling, and enhance tumor resistance to chemotherapy by reducing drug
uptake (Loeffler et al., 2006) (Fig. 1-2).
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Figure 1-2. Proposed functions of ASC in adipose tissue remodeling and tumor
progression. The hypothetical mechanisms through which ASC promote adipose tissue
expansion, by contributing to preadipocyte pool to differentiate into mature adipocytes and
support adipose tissue vasculatures functioning as pericytes and provide growth factors
(shown in green arrows). ASC modulate extracellular matrix (ECM) components and
rigidity to support adipose tissue expansion and stimulate tumor growth. In cancer, ASC
may serve as source for adipocytes and cancer associated fibroblast (CAF), secreting proinflammatory cytokines to promote tumor survival and growth. ASC support tumor
vasculature by incorporation into tumor vessel lumen (shown in blue and green arrows).
Figure obtained with permission of Springer from book chapter “Tseng C & Kolonin MG. Adipose TissueDerived Progenitor Cells and Cancer. In: Angiogenesis in Adipose Tissue. Springer, New York, 2013,
pp321-337
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Adipose Tissue Expansion
Adipose tissue, the energy repository in mammals provides a long-term fuel reserve
for future need. In the event of energy overload, surplus energy is stored as triacylglycerols
in adipocytes (Cinti, 2005). In contrast, the high energy fuel triacylglycerols are readily
mobilized when energy is deficient. To meet the demand of constant energy fluctuations,
adipose tissue is highly plastic and possesses the unique capability to retract and expand in
a non-transformed state (Sun et al., 2011). Adipose tissue expansion, like any other tissue
expansion, requires angiogenesis and structural remodeling (Cao, 2010). The formation of
new vasculature is key in supplying cells, oxygen, growth factors and cytokines to
facilitate tissue growth, repair and expansion. In addition, it is also crucial for removal of
metabolic wastes.
The healthy expansion of adipose tissue relies on controlled changes in ECM components
parallel with orchestrated events coordinated by hypertrophy and hyperplasia of various
cell types including adipose progenitor cells, endothelial progenitor cells, and infiltrating
immune cells (Sun et al., 2011). Adipose progenitor cells are capable of differentiating into
adipocytes while endothelial progenitor cells incorporate and facilitate neovascularization.
Immune cells such as macrophages provide growth, survival and angiogenic factors. The
interplay of these cells is crucial in development of functional adipose tissue (Wernstedt
Asterholm et al., 2014).
However, pathological expansion of adipose tissue ensues when the aforementioned
processes are disrupted; resulting in poorly perfused hypoxic adipose tissue. Hypoxic
adipose tissue is associated with inflammation and increased fibrosis. Hypoxia-inducible
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transcription factors increase proinflammatory cytokines expression and migratory ability
in activated macrophages (Imtiyaz et al., 2010). Ectopic overexpression of degradation
resistant HIF-1α in mouse adipocytes showed an upregulation of ECM components
including collagens, lysyl oxidase (LOX) and elastin (Sun et al., 2011). Abnormal
deposition of these matrix components leads to hypoxia-induced fibrosis in AT.
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Toward mechanisms controlling ASC mobilization
Cell mobilization is a term describing recruitment of a cell from its original niche
into the circulation. This cascade of events involves multiple steps and interplays of
different factors including adhesion molecules, proteases, cytokines and chemokines. For
instance, upon granulocyte colony-stimulating factor (G-CSF) treatment, bone marrow
residing cells respond by inducing proteases expression of matricellular factors that reduce
hematopoietic stem cell (HSC) adhesion with its immediate surrounding matrix. In parallel,
up-regulation of proteases and chemokines facilitate mobilized cells to traffic and
extravasate into circulation (Petit et al., 2002). Homing of mobilized cells is dictated by a
chemokine gradient. Although the molecular mechanisms governing ASC mobilization
remained elusive, extensive clinical studies on haemapiotic stem cells led us to hypothesize
that a similar mechanism underlies ASC mobilization.
Pathological expansion of tissues such as WAT in obesity or tumor growth in
cancer progression, lead to inadequate oxygenation, creating hypoxic microenvironment
within the organ (Bertolini et al., 2012). Hypoxia is a robust inducer of inflammatory and
chemotactic factors, which promotes macrophage infiltration by upregulation of monocyte
chemotactic proteins (MCP)-1, -1α, -2, -3, and RANTES expression in adipose tissue (Ota,
2013; Surmi and Hasty, 2008). In tumors, hypoxia induces upregulation of stromal cellderived factor (SDF-1) in tumor-associated fibroblasts and promotes recruitment of
CXCR4 expressing macrophages (Murdoch et al., 2004). Similarly, augmented CXCR4
expression in ASC is observed in ischemic conditions (Thangarajah et al., 2009). A recent
study showed microperfusion of mouse fat pad with a CXCR4 antagonist increased ASC
release, suggesting the involvement of the CXCL12/CXCR4 axis in regulating ASC
19

retention/migration in vivo (Gil-Ortega et al., 2013). Furthermore, glucagon-like peptide-1
receptor agonist stimulates ASC migration by upregulation the SDF-1/CXCR4 signaling
cascade and p-Akt activity (Zhou et al., 2015). Interestingly, the CXCL12/CXCR4
signaling axis is also shown to be involved in HSC and endothelial progenitor cell
mobilization and blockade of this signaling axis partially disrupts the recruitment of
progenitor cells to the ischemic heart tissue (Abbott et al., 2004; Liu and Velazquez, 2008).
Consistent with ASC displaying tropism to inflammatory cues, activation and increased
mobilization of ASC are reported in both obesity and cancer. Our group and others
reported expression of chemokine receptors: CCR1, CCR4, CCR7, CXCR1, CXCR2 and
CXCR5 on ASC in response to inflammation stimuli (Klopp et al., 2012; Ponte et al., 2007;
Von Luttichau et al., 2005). An increased in expression of chemokine (C-C motif) ligand
(CCL)-2, -3, -5, -7, -8, -11 and chemokine receptors (CCR)-1, -2, -3, and -5 are observed
in both subcutaneous and visceral AT of obese patient (Huber et al., 2008). However, the
role of theses chemokines in modulating ASC migration remained to be determined.
Similarly, the concomitant upregulation of CXCR1 and CXCR2 on ASC may be
responsible for directing their migration in response to CXCL1 and IL-8 secreted by
endometrial cancer cells (Klopp et al., 2012). The complex signaling networks of ASC
migration in cancer remained unclear.
In cell mobilization, in addition to chemokine/chemokine receptor-directed ASC
trafficking, the modulation of cell contacts with its microenvironment is key in regulating
cell motility. Strong adhesion of cells to its niche prevents cell migration. Tissue expansion
induces factors involved in ECM remodeling. One of such matricellular molecules is
SPARC (secreted protein acidic rich in cysteine) (Kos and Wilding, 2010). SPARC is
20

known to control cell-cell interaction and cell adhesion. Previously, our group showed that
binding of the SPARC to β1 integrin on ASC surface promotes cell migration, implicating
the role of SPARC in cell mobilization (Nie et al., 2008). Indeed, SPARC has been shown
to activate fibroblast migration in myocardial infarction models (Takahashi et al., 2001).
Clinical data on elevated SPARC concentration in plasma of obese individual is consistent
with the possibility that SPARC induces ASC deadhesion and migration, facilitating its
incorporation into new WAT vessel during tissue expansion. Likewise, a similar
mechanism maybe involved in tumor vascularization supported by elevated SPARC level
in serum of cancer patients (Ikuta et al., 2005).
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SECRECTED PROTEIN ACIDIC RICH IN CYESTEINE (SPARC)

SPARC PROTEIN STRUCTURE

Figure 1-3. Functional domains of SPARC. SPARC consists of three distinct domains:
acidic domain (red), the follistatin-like domain (grey) and extracellular calcium binding
domain (green). The functional properties of distinctive domain and its interacting proteins
are shown.
SPARC, also named as osteonectin when initially found in bone (Bolander et al.,
1988), and BM-40 when discovered in the basement-membranes (Dziadek et al., 1986) , is
a non-structural matricellular protein that is highly conserved across different species. The
positions of cysteine residues within SPARC are found to be highly homologous among
species, suggesting the importance of the 3D structure to its function.
SPARC has a molecular weight of 34kDa and migrates to 43kDa on sodium dodecyl
sulfate polyacrylamide gel electrophoresis due to glycosylation. The signaling peptide of
SPARC (17 amino acids) is removed during processing generating the mature SPARC.
Mature SPARC consists of three domains, namely the N-terminal acidic domain (Ala1Glu52), follistatin-like (FS) domain (amino acid Asn53-Pro137) and extracellular calcium
(EC) -binding domain (Cys138-Ile286) (Chlenski and Cohn, 2010). Each domain has been
reported to exhibit distinct functions (Figure 1-3). The N-terminus of SPARC has low
22

calcium ion binding affinity (Kd 10mM), bears the transglutaminase cross linking amine
acceptor sites and was recently found to have a chemosensitizing role through activating
caspase 8 signaling (Rahman et al., 2011). Synthetic peptides spanning regions of the
SPARC N-terminus possess cells spreading inhibition ability (Lane and Sage, 1990) and
also activates MMP2 (Gilles et al., 1998).
The structural morphology of the cysteine-rich FS domain of SPARC bears resemblance to
the epidermal growth factor, supported by conserved distribution of the disulfide bonds
(Chlenski et al., 2004). This region of SPARC binds multiple factors including inhibin,
activin, heparin and proteoglycans. FS domain is a potent antagonist of angiogenesis and
cell migration. Interestingly, it also bears the pro-angiogenic copper binding sequence
KGHK (Bradshaw and Sage, 2001). The synthetic peptide spanning EGF module of the FS
domain promotes fibroblast proliferation, disrupts endothelial cell focal adhesion, and
inhibits its entry into S phase of the cell cycle (Chlenski et al., 2004).
The C-terminal EC-domain consists of two EF-hand motifs that bind calcium ions with
high affinity Kd (0.08-0.6M). Point mutations and deletion studies of this region
identified the critical collagen binding sites consisting of residues R149, N156, L242,
M245 and E246 (Sasaki et al., 1998). Single-bond peptide cleavage by an unknown
protease or metalloproteinases within the EC-domain of SPARC increases its collagen
binding affinity (Hohenester et al., 2008; Sasaki et al., 1998). The function of the synthetic
peptide spanning the second EF-hand domain interferes with growth factors such as VEGF,
PDGF and bFGF signaling, inhibits endothelial cell growth and disrupts focal adhesions
(Chlenski and Cohn, 2010).
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SPARC FUNCTION
SPARC is a multifunctional glycoprotein that is found to be ubiquitously expressed
in various tissues. Upregulation of SPARC is commonly reported in tissues undergoing
active tissue remodeling such as tissue renewal, tissue repair, mineralization, angiogenesis,
embryonic development and tumorigenesis (Chlenski et al., 2004). Only limited basal
expression is found in non-remodeling adult tissues. Elevated SPARC expression promotes
fibroblastoid cells migration in myocardial infarction and also facilitates adipose tissue
expansion (secreted protein acidic rich in cysteine) (Wu et al., 2006). Among the
multifunctional roles of SPARC, it is best recognized as a modulator of cell-extracellular
matrix (ECM) contact, cell-cell interactions, ECM deposition and migration (Naimi and
Van Obberghen, 2009). SPARC disengages and induces rounding of bovine aortic
endothelial cells (Sage et al., 1989) and enhances ASC migration (Nie et al., 2008). Further
evidence links the counter-adhesive characteristic of SPARC to its ability to disrupt focal
adhesion assembly and promote rearrangement of stress actin fiber in endothelial cells
(Murphy-Ullrich et al., 1995). The multifaceted SPARC activities are mediated by
interacting with the ECM proteins and several cellular surface receptors, including
VCAM1, stabilin-1, and integrins.

24

SPARC in Extracellular Matrix (ECM) Remodeling
ECM comprises of two major types of macromolecules, namely the fibrous
proteins and the proteoglycans. The fibrous proteins composed of collagens, fibronectin,
laminins and elastins (Frantz et al., 2010). In the ECM, SPARC binds to multiple
components including collagens (type I, II, III, IV and V), thrombospondin 1, entactin and
vitronectin (Chlenski et al., 2004). Among these ECM components, the interaction of
SPARC with collagens is best characterized. Collagens, the most abundant structural
protein in vertebrate tissues provide mechanical support for protein anchorage or cell
attachment. The proper formation of collagen fibers is critical to maintain tensile strength
of tissue and retains its normal morphology. SPARC serves as a chaperone in modulating
collagen fibril formation and incorporation of it into the ECM (Rentz et al., 2007). As
SPARC is present in the secretary pathway, it is proposed to interact with collagen I and
affect collagen I assembly and trafficking (Martinek et al., 2007). A study utilizing a
SPARC mutant (Val196-Phe 203 deletion) which mimics activation by proteolysis,
showed a drastic inhibition of collagen fibrillogenesis (Giudici et al., 2008).
Additional factors that have been shown to affect SPARC association with collagens
include calcium concentration, proteases processing and glycosylation. SPARC derived
from bone consists of high mannose and biantennary glycans, thereby shows a differential
binding affinity to collagen I and V compared to platelet-derived SPARC that are
decorated with bi and triantennary glycans (Chlenski et al., 2004). Furthermore, a previous
study showed that absence of N-glycosylation at residue 99 significantly increases the
capacity of SPARC binding to collagen V. This disparity in binding may be partly
attributed to masking/unmasking of specific collagen binding sites on SPARC (Xie and
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Long, 1995). EDTA chelation of calcium ions disrupts SPARC/ collagen binding. SPARC
is a substrate for several extracellular proteases, producing bioactive proteolytic fragments.
Single-bond peptide cleavage by an unknown protease or metalloproteinase within the ECdomain (Pro237-Leu238) of SPARC increases its collagen binding affinity without
changing its -helical conformation. Point mutation and deletion studies of this region
identified the critical collagen binding sites consisting of residues R149, N156, L242,
M245 and E246 (Sasaki et al., 1998).
To evaluate the physiological function of SPARC, SPARC-null mice in various transgenic
backgrounds have been generated (Gilmour et al., 1998; Norose et al., 2000). Adult
SPARC-deficient mice present with reduced collagen content in the dermis and harbor
only approximately half the tensile strength compared to WT mice (Bradshaw et al.,
2003b). Early onset of cataractogenesis results from irregular distribution of laminin and
collagen IV in the lens capsule basement membrane is another prominent phenotypic
abnormalities of SPARC-deficient mice (Bradshaw et al., 2003b; Norose et al., 2000).
Proper matrix protein deposition in the lens capsule is critical for physiological
permeability of the tissue (Norose et al., 2000). This impairment contributes to
pathological changes in the ions and fluid balance across the basement membrane.
SPARC- deficient mice also have reduced collagen deposition in bone and lower
osteoblast and osteoclast numbers (Delany et al., 2000). This absence of SPARC in bone is
proposed to result in impairment of linking organic and mineral phases of the bone tissue
(Long, 2001; Mansergh et al., 2007). SPARC-deficient mice progress to severe osteopenia
by 6 months of age. The early development of osteopenia is also partly attributed to the
decreased synthesis of new bone by osteoblasts (Delany et al., 2000). Interestingly, the
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reduced bone mass is accompanied by a higher adiposity in the SPARC-deficient mice
(Bradshaw et al., 2003b). Overall, the absence of SPARC results in phenotypic
abnormalities that is mostly associated with aberrations in ECM structure and assembly
defect.
ECM assembly and deposition are greatly influenced by extracellular proteases. Matrix
proteases degrade ECM components to facilitate tissue remodeling. An additional
mechanism by which SPARC affects ECM remodeling is through modulating
metalloproteinase expression by cells. SPARC promotes MMP1, MMP3, and MMP9
expression in fibroblasts; MMP1 and 9 in monocytes; and up-regulation of MMP2 activity
in cancer cells (Chlenski and Cohn, 2010).
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SPARC and Obesity
In obesity, the infiltration of pro-inflammatory cells into the tissue produces
cytokines that change the dynamics of ECM deposition. These changes result in a more
fibrotic tissue microenvironment characterized by increased ECM proteins expression such
as integrins, type IV collagen, lumican and laminin 1 chain (Kos and Wilding, 2010).
Excessive ECM deposition leads to increased rigidity of tissues and disrupts the normal
tissue function and architecture. Previous studies identified SPARC as one of the key
factors up-regulated in obesity (Tartare-Deckert et al., 2001). Elevated SPARC expression
is observed in both obese human and mouse adipose tissue as compared to lean human and
mouse. The serum levels of SPARC correlate with adiposity of human and fluctuate in
accordance to the changes in BMI, suggesting adipose tissue to be the major source of
SPARC in obesity. Given the capability of SPARC to modulate collagen deposition and its
association with obesity, SPARC is proposed to be a pro-fibrotic factor. Consistent with
such a role, a lower streptozoticin-induced renal fibrosis is detected in SPARC-deficient
mice as compared to the wild-type mice (Taneda et al., 2003). In addition to directly
affecting ECM deposition, SPARC induces pro-fibrotic protein Transforming Growth
Factor- (TGF-) expression. TGF- stimulates fibroblasts to contract ECM and synthesize
matrix proteins such as collagen and fibronectin (Leask and Abraham, 2004).
The adipocytes are the predominant secretor of SPARC in obesity. Phenotypic
characterization of adipose tissue in wild type or SPARC-deficient mice demonstrated
significantly increased adiposity with increased adipocyte number and cell size in SPARCdeficient mice compared to wild-type mice (Nie and Sage, 2009). SPARC limits
adipogensis by stimulation of the wnt/β-catenin signaling pathway and has been shown to
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inhibit adipose stromal cell differentiation into adipocytes. Exogenous SPARC treatments
decrease adipogenic transcription from genes. Consistently, SPARC-deficient marrow cells
have higher adipsin and CCAAT/enhancer binding protein delta expression and display
increased propensity towards adipocyte differentiation (Delany et al., 2003). SPARC
expression during adipogenesis is biphasic, which spikes in preadipocytes during early
stage of differentiation, followed by a drop as differentiation progresses. However, SPARC
level eventually rises in mature adipocytes (Nie and Sage, 2009).
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SPARC Proteolysis
The ECM is highly versatile and undergoes constant remodeling, i.e. assembly and
degradation (Daley et al., 2008). Remodeling of ECM involves modification and
degradation by proteases. This post-translational proteolytic protein processing is
important in influencing the ECM microenvironment. ECM is crucial in providing
structural and biochemical support to cells and dictates diverse biological events including
cell growth, survival, differentiation and migration (Brekken and Sage, 2001). The matrix
metalloproteinases (MMPs) are among the best-studied proteases involved in ECM
degradation. In addition to cleaving the structural components of ECM, MMPs also target
a wide range of non-structural ECM proteins.

Matricellular protein SPARC is a substrate for numerous extracellular proteases. Cleavage
of SPARC produces bioactive fragments with distinct functions that are contextual. For
example, limited proteolysis of recombinant SPARC by MMP3 generates 3 major
fragments in vitro. These truncated derivatives modulate cell growth, cell migration and
angiogenesis distinctively (Sage et al., 2003). In addition, SPARC proteolysis occurring in
chicken chorioallantoic membrane is associated with pro-angiogenic properties (IruelaArispe et al., 1995) and cathepsin K-cleaved SPARC promotes bone metastasis (Podgorski
et al., 2009). Limited proteolysis of SPARC modulates collagen binding. Sasaki reported
that cleavages of SPARC by unknown proteases or MMPS at in the EC domain residue
L198, increases SPARC binding affinity for collagens. The proteolytic cleavage revealed
masked epitope for collagen on SPARC, thereby increasing its affinity for collagen binding
(Sasaki et al., 1997; Sasaki et al., 1998; Sasaki et al., 1999).
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SPARC and ASC
Matricellular protein SPARC abundantly secreted by adipocytes is also secreted by
adipose tissue-residing cells including fibroblasts, endothelial cells, pericytes and
macrophages. SPARC has reported functions in influencing migration, mobilization and
cellular structure. SPARC expression is transiently upregulated in injured myocardium and
stimulates fibroblast migration, a process critical in wound healing (Wu et al., 2006). A
counter adhesive role of SPARC induces endothelial cell rounding (Murphy-Ullrich et al.,
1995) and increases endothelial permeability (Goldblum et al., 1994). SPARC regulates
pericytes migration through interacting with TGF-1 accesory receptor endoglin (Rivera
and Brekken, 2011). The functional role of SPARC specifically in progenitor cell
physiology remained unexplored. Our group identified SPARC as an ASC-interacting
protein by characterizing ASC surface proteomic using phage display combinatorial
random peptide library. These studies identified of the ASC surface SPARC receptor of to
be 5 1 integrin (Nie et al., 2008; Weaver et al., 2008). The binding of SPARC to 1
integrin at focal adhesions on ASC is associated with changes in cellular structure
resembling focal adhesion disassembly, mediating an intermediate cell adhesion state
which favor cell migration (Nie et al., 2008).
In obesity, adipose tissue undergoes remodeling to accommodate energy surplus. The
expansion of WAT relies on angiogenesis, differentiation of preadipocytes and ECM
remodeling. Formation of new vasculature to support healthy WAT expansion involves
mobilization and proliferation of progenitor cells. Elevated SPARC expression in obesity
may contribute to ASC migration by binding to 1 integrin at focal adhesions, modulating
ASC and ECM interactions. This event along with chemokine receptors CCR1, CCR4,
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CCR7 and CXCR5 that are over expressed on ASC induced by inflammation stimuli
(Klopp et al., 2012; Ponte et al., 2007; Von Luttichau et al., 2005), promotes ASC
mobilization. Subsequent studies are required to elucidate the complex signaling networks
involved in regulating ASC migration in response to obesity.
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Integrin and Cell Adhesion
Integrins are transmembrane adhesion receptors expressed on cells as
noncovalently-linked heterodimeric α and β subunits. In mammals, there are 18 -integrin
and 8 -integrin subunits; heterodimerization of these subunits produces 24 distinct
integrin heterodimers (Iwamoto and Calderwood, 2015). Integrin receptors are involved in
cell adhesion to surrounding ECM proteins, generating signals critical for cellular
processes that occur during development, immune response and progression of diseases
(Hynes, 2002). Integrins bind a variety of matrix molecules ranging from ECM proteins,
cell surface, or other soluble factors. The integrin repertoire expressed by a specific cell
determines its ECM binding dynamic. Pertinent to our study, 51 integrin binds to
fibronectin while 11 integrin binds to collagen. In addition to being an adhesion receptor,
integrin directs intracellular signaling. The cytoplasmic domain of integrin associates with
the intracellular focal adhesion (FA) complex proteins such as Focal adhesion kinase (FAK)
and integrin-linked kinase (ILK) (Veevers-Lowe et al., 2011). Ligand binding results in
integrin conformational changes and subsequently induces integrin clustering and
formation of mature adhesion complex. More than 150 proteins have been identified within
the adhesion complex including intracellular signaling components, adaptor proteins that
interact with actin cytoskeletons. FAK is one of the major kinases involved in mediating
signal from integrin to regulate focal adhesion, cell motility and shape. In general, integrin
activation leads to FAK autophosphorylation at tyrosine 397 which allows recognition by
SH2-containing proteins (SRC-family kinases) that subsequently bind and phosphorylate
the adaptor protein paxillin as well as additional FAK sites. The FA signaling is highly
complex and composition of FA varies according to its location. Molecular compositions
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of FA at the cell edge are reported to be distinct from the core (Ivaska, 2012; Mitra et al.,
2005).
Cell adhesion is central for cell motility. Strong adhesion of cells to extracellular
substratum impedes the cell’s ability to move, while low adhesion fails to provide
sufficient traction to facilitate cell movement. Therefore, the maximum cell motility is
observed in an intermediate adhesion regulated by the integrins and the concentrations of
the ligands (Vicente-Manzanares et al., 2005).
FAs undergo assembly and dissociation during cell migration. As the cell migrates, it is
polarized. Adhesion contacts are formed at the leading edge to provide traction force while
disassembly and retraction of the rear involves disrupting integrin-ECM or integrincytoskeleton interaction (Lo, 2006; Nagano et al., 2012).
We and others have previously shown that SPARC associates with 51 integrin (Nie et
al., 2008; Weaver et al., 2008). This association on ASC is found to be localized to FAs.
Given the counter-adhesive role of SPARC, it was proposed that SPARC interferes with
51 binding to fibronectin which creates intermediate cell adhesion that facilitates cell

mobility. Additional studies such as gain-of-function or loss-of-function of components
involved in SPARC signalings are required to elucidate the precise mechanism involved in
SPARC- induced cell rounding.
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Focal Adhesion Kinase (FAK) and Integrin-linked kinase (ILK)
FAK, a non-receptor tyrosine kinase, first identified in 1992 (Parsons, 2003), is a
major integrin- signaling protein localized to adhesion contact. FAK is expressed on most
cells and serves as a central mediator of integrin signaling or other growth factors (Mitra et
al., 2005; Parsons, 2003). FAK regulates a diverse array of biological functions including
cell migration, cell survival, and cell cycle progression and growth factor signaling
(Parsons, 2003; Zhao and Guan, 2011). FAK-null mutant mice are embryonic lethal
characterized by profound mesodermal defects and FAK-deficient fibroblast form
excessive focal contact and showed abnormality in their capacity to migrate. These
phenotypes suggest that FAK is crucial in cell migration and modulating integrin-mediated
adhesion disassembly (Mitra et al., 2005). Integrin engagement transduces outside-toinside signals through activating FAK, characterized by increase in Tyr397
autophosphorylation. Following activation of FAK, SH2- and SH3-domain-containing
proteins are recruited to the site, which mediate subsequent downstream signalings
including the action of Rho family GTPases Rac and Cdc42, controlling cellular
attachment, extension and retraction coordinated with actin-myosin cortex redistribution
(Mitra et al., 2005; Parsons, 2003).
During cell migration, FA bindings to ECM provide traction force to pull the cell body
forward. Subsequently, disruption of FA at the cell rear is essential to allow cell movement.
The process of FA turnover is regulated by FAK. FAK phosphorylation at Tyr397 promotes
recruitment of protein complex that are involved in integrin endocytosis. Dissociation of
FA complexes and integrin endocytosis is associated with rapid dephosphorylation of FAK
at Tyr397(Nagano et al., 2012).
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In addition to FAK, Integrin-linked kinase (ILK) is another well known integrininteracting protein localized to FA (Widmaier et al., 2012). Both kinases constitute the FA
signaling complex and are involved in mediating integrin signaling, thus may be partially
interdependent (McDonald et al., 2008). ILK is an important mediator of integrin signaling
regulating a wide array of processes such as cell growth, survival, differentiation and
migration. Multiple studies in development and caner have demonstrated the role of ILK in
modulating cell migration. Ligand binding to integrin leads to ILK activation which
subsequently activates a diverse downstream effectors including glycogen synthase kinase
3 (GSK3) (McDonald et al., 2008).
Previous studies shown that FAK and ILK as proteins functionally engaged with SPARC
modulating cell migration and survival (Nie et al., 2008; Shi et al., 2007; Weaver et al.,
2008). However, their role in ASC migration remained unclear. Based on the role of ILK
and FAK in cell migration, we hypothesized that SPARC/1 signaling through these
kinases is essential to induce ASC migration which leads to their mobilization.

36

Chapter 3
Methods and Materials

Part of this chapter is taken verbatim by permission from the Stem Cells: Chieh Tseng and
Kolonin, Proteolytic Isoforms of SPARC Induce Adipose Stromal Cell Mobilization in
Obesity, Stem Cells, Epub ahead of print.
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3-1. Mice
All animal experimentations complied with protocols approved by UT Health Animal Care
and Use Committee. Mouse strains C57BL/6, GFP-mice (UCP-GFP) and RFP-mice
(ACTB-mRFP1)(Zhang et al., 2012) were purchased from Jackson. SPARC-/- mice were
received from Dr. Helene Sage. For diet-induced obesity, mice were given fed high-fat
(HFD) (60 kcal% fat) diet D12492, regular chow (13.1 kcal% fat) or low-fat diet (LFD)
D12450B (10 kcal% fat) from Research Diets, New Brunswick, NJ. EchoMRI-100T (Echo
Medical Systems) was used to measure adipose tissue mass and lean mass as described
(Taicher et al., 2003). For tumor engraftment, 2.5x10^5 EO771 breast adenocarcinoma
cells were subcutaneously injection into the mammary fat pat with 21-gauge needle.
Tumor size was measured weekly with a caliper; tumor volume was calculated as (length
X width2 X 0.52). All mice were housed and care for in a standard 12 hours light/dark
cycle, in accordance with institutional standards. Mice were carbon-dioxide-euthanatized
prior to tissue extraction.
3-2. Cell isolation and culture
For isolation of stromal vascular fraction (SVF), adipose tissues from C57BL/6 WT
and SPARC-/- mice were resected from various adipose depots (subcutaneous,
intraperitoneal and epididymal), minced, and digested with collagenase (Worthington 250
U/ml in PBS) and dispase ( Roche, 2.4U/ml in PBS) for an hour at room temperature with
intermittent shaking. Preparations were passed through a 40 μm mesh and centrifuged at
400g for 8 min. The SVF pellets were washed and resuspended with alpha-MEM. The
SVF pellets were subjected to immunostaining, flow cytometry analysis, Western blotting,
or culture. ASC, enrichment for which was confirmed by flow cytometry using CD34,
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CD31, and CD45 as markers, were cultured in alpha-MEM supplemented with 10% FBS
and penicillin/streptomycin. To obtain peripheral blood mononucleated cells (PBMC),
whole blood was collected from cardiac puncture of euthanized mice. The anticoagulanttreated blood was gently layered onto Ficoll-paque solution (GE) and centrifuged
(Eppendorf centrifuge 5810R) at 2000rpm 20min, brake 0. The buffy coat layer enriched
with mononuclear cells was collected and washed with alpha-MEM or fluorescenceactivated cell sorting solution (2%BSA/1 mm EDTA) then subjected to flow analysis. 3T3L1 and HEK 293 cells (purchased from American Type Tissue Collection) were cultured
in Dulbecco's Modified Eagle's Media containing 10% fetal bovine serum (FBS)
supplemented with 10% FBS and penicillin/streptomycin. Breast adenocarcinoma E0771
(from F.M.Sirotnak) was cultured in RPMI supplemented with 10% FBS supplemented
with 10% FBS and penicillin/streptomycin.
3-3. Flow cytometry
For fluorescence-activated cell sorting (FACS) analysis, peripheral blood
mononucleated cells (PBMCs) were obtained by Ficoll-sodium metrizoate centrifugation
procedure (GE Health). PBMC or SVF cells (used as a gating control) were pretreated with
red blood cell lysis buffer and stained with respective antibodies. Cells were prepared at a
concentration of 1 million cells per milliliter and pregated to exclude non-viable cells,
tissue debris, cell clumps, red blood cells based on 40,6-diamidino-2-phenylindole staining.
Live PBMCs were sorted into populations as described with FACSAria/FACSDiva
software based on the IgG clones: eFluor 660-conjugated rat anti-CD34 (RAM34,
eBioscience, 1:100), PE conjugated rat anti-CD312 (MEC 13.3, BD Biosciences, 1:100),

39

and APC-cy7-conjugated rat anti-CD45 (30-F11, BD Biosciences,1:100). Gating was
based on the corresponding isotype controls (BD Biosciences, San Jose, CA).
3-4. Transwell assay
Cell migration assays were conducted as described (Corning, USA). Cells were seeded
(triplicate) in 200 μl of 0.1% FBS medium. Inserts were placed in wells containing 700 μl
of 5% or 0.1% FBS medium supplemented with SPARC or indicated SPARC isoforms,
10% FBS was used as positive control. The cells were incubated for 16 hr. Non-migrated
cells retaining in the insert were removed gently by swabbing with a cotton swab. The
inserts were fixed with 4% paraformaldehyde for 10 min at room temperature and stained
with crystal violet. Migrated cells attached on the other side of the insert were counted
using a bright-field microscope.
3-4. Tissue processing and immunofluorescence microscopy
Tissues obtained were processed as previously described (Zhang et al., 2009),
briefly, formalin-fixed and paraffin embedded 5 mm tissue sections were subjected to
Novocastra antigen retrieval solution (Leica, Buffalo Grove, IL), washed with Phosphate
Buffered Salt (PBS) containing 0.01% Triton-X, and blocked in serum-free protein block
(DAKO, Carpinteria, CA). For preparation of WAT whole mounts, fragments of WAT
were partly digested with collagenase/dispase for 15 minutes at room temperature and
washed with PBS. Whole mounts or SVF cells, preincubated with SPARC proteins (100
nM) for 30 minutes where indicated, were prepared for immunofluorescence by washing
with PBS and fixing with 4%
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paraformaldehyde for 10 minutes at room temperature, rendered permeable with 0.3%
Triton X-100 for 5 minutes, and blocking with Seablock (Thermo scientific, Waltham, MA)
for 1 hour at 24 oC. Samples were incubated at 4 oC overnight with primary antibodies as
follows: mouse anti-SPARC monoclonal antibody Mab303 (gift from Helene Sage, 1:100),
goat anti-mouse SPARC (R&D Systems, Minneapolis, MN, 1:100), rabbit anti-perilipin
(Cell Signaling Technology, Danvers, MA, 1:100), rat anti-mouse F4/80 (Abcam,
Cambridge, MA1:100), rat anti-CD34 (Abcam, 1:100), rabbit anti-stabilin-1 (Santa Cruz,
Santa Cruz, CA,1:100), rat anti active b1 integrin 9EG7 (BD Pharmingen, San Diego,
CA,1:100), rabbit anti-paxillin Tyr118 (Cell Signaling Technology, Beverly, MA, 1:100),
phalloidin (Invitrogen, Carlsbad, CA, 1:40), or biotinylated isolectin B4 (Vector
Laboratories, Burlingame, CA,1:75). Following washing, the samples were incubated with
secondary antibodies at room temperature for 1 hour in PBS/0.01% Triton-X. Secondary
antibodies used were donkey Alexa 488-conjugated IgG (Invitrogen, 1:150) and Cy3conjugated IgG (Jackson ImmunoResearch, West Grove, PA, 1:300). Nuclei were
stained with Hoechst 33258 or DRAQ5 (Cell Signaling Technology, 1:1,000). Samples
were mounted in ProLong Gold Antifade Mountant (Life Technologies, Austin, TX).
Image acquisition was done using confocal Leica TCS SP5 microscope (images captured
using Plan Apo 310/0.40CS, 340/0.75 U-V-I) and analyzed using LAS AF software or
with Olympus IX70 (Center Valley, PA) inverted fluorescence microscope (images taken
with 310/0.25, 320/0.40, or 340/0.60) using Olympus DP71 camera. Images were analyzed
with cell-Sens software. Staining with secondary antibodies alone was used to set threshold
and exclude nonspecific signal. All images were acquired at room temperature. Brightness
and contrast of images were adjusted with Adobe Photoshop CS3.
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3-5.Short-hairpin RNA (shRNA) lentiviral production and infection
1

integrin,

ILK,

FAK

silencing

experiments

were

performed

with

lentiviral pLKO.1-puro vectors from Sigma-Aldrich (St. Louis, MO). The following
oligonucleotides were used: TRCN0000066645 and TRCN0000066646 for b1integrin;
TRCN0000023484

and

TRCN0000023488

for

FAK,

TRCN0000022515

and

TRCN0000022517 for ILK. Green fluorescent protein (GFP)-short-hairpin RNA (shRNA)
PLKO.1 was used as untargeted shRNA control. 293T cells were co-transfected with
indicated protein shRNA or control shRNA carrying GFP tag, packing plasmids
(deltaVPR8.9) and envelope plasmid (VSV-G) using Lipofectamine 2000 reagent
according to the manufacturer’s instructions or calcium phosphate for 2 days, and virus
particles containing indicated protein or control shRNAs were filtered through 0.45 µm
pore cellulose acetate membranes and used to infect 3T3L1 cells. All the infected cells
were cultured and puromycin (2 μg/ml) medium selection medium for 4 days. The
knockdown efficiency was validated by western blotting.

3-6. ILK kinase assay
The ILK kinase assay was performed according to the manufacturer’s protocol (Cell
Signaling Technology, Nonradioactive Akt Kinase Assay Kit) with some modifications.
3T3-L1 cells (or immortalized mouse ASC (Zhang et al., 2009) used with the same result)
transduced with indicated silencing constructs were serum-starved for 24 hr before
incubation with SPARC or SPARC isoforms for 10 min. Cells were washed with PBS,
harvested and lysed with cell lysis buffer. Lysate (500 g) were immunoprecipitated with 2
g of goat anti-ILK antibody (Santa Cruz) at 4oC overnight. Protein A/G plus agarose
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beads were used to pull down immune complexes (Thermo Scientific), followed by 3
washes with cell lysis buffer. The isolated immune complexes were then incubated with 1
g GSK-3 fusion protein subtract in reaction buffer containing 200 M ATP, for 30 min
at 30°C. Western blotting with rabbit anti-phospho-GSK-3 / (Ser21/9) antibody (Cell
Signaling Technology, 1:1000) was use to detect substrate phosphorylation.
3-7. Western blot analysis
Cells were lysed with radio-immuno-protein assay (RIPA) buffer (150 mM sodium
chloride, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, and 50 mM Tris, pH 8.0, protease inhibitor cocktail (Roche). The protein
concentration was determined with Bradford protein assay (Pierce, Appleton, WI). An
equal amount of protein/lane was loaded onto 10% polyacrylamide SDS Tris–Glycine gels.
After electrophoresis (20 mA/gel), proteins were electroblotted onto polyvinylidene
fluoride (PVDF) membranes (Millipore, Billerica, MA). Membranes were blocked (5%
nonfat dry milk) and then incubated with primary antibody overnight at 4oC, followed by
incubation with horseradish peroxidase (HRP)-conjugated secondary antibody at room
temperature for 1 hr. The blots were developed by using enhanced chemiluminescence
(Pierce). Mouse anti--actin antibody was from Sigma (1:5000). Goat anti-1 integrin and
anti-ILK antibodies were from Santa Cruz Biotechnology (1:1000). Goat anti-SPARC
(R&D Systems), mab303, rabbit anti-FAK (Abcam) and rabbit anti-phospho-FAK (pY397)
(Invitrogen) were used at 1:1000. Rabbit anti-Akt, anti-phospho-Akt (S473), anti-phosphopaxillin (Tyr118), anti-ERK, and anti-phospho-ERK1/2 (Thr202/Tyr204) antibodies were
from Cell Signaling Technology (1:1000).
3-8. Expression and purification of recombinant proteins
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The cDNA encoding SPARC and its truncated fragments were PCR-amplified
using the SPARC cDNA as a template, cloned into vector pcDNA3.1 and sequenceverified. Human embryonic kidney 293 (HEK-293) cells were transiently transfected with
the vectors by calcium phosphate precipitation. Empty vector for expression was used as a
negative control. The recombinant His-tagged proteins were purified from conditioned
culture media by Ni-NTA-Bind Resin (Novagen, Madison, WI) according to
manufacturer’s protocol with minor modifications. Briefly, the Ni-NTA-Bind resin slurry
was pre-washed with 1X Ni-NTA bind buffer (50 mM NaH2PO4, pH 8.0; 300 mM NaCl;
10 mM imidazole) and mixed with conditioned medium for an hour at 4oC. The proteinresin complex was packed into column for subsequent wash (1X Ni-NTA Wash Buffer: 50
mM NaH2PO4, pH 8.0; 300 mM NaCl; 20 mM imidazole) and elution (1X Ni-NTA Elute
Buffer: 50 mM NaH2PO4, pH 8.0; 300 mM NaCl; 250 mM imidazole). The eluted Histagged proteins were subjected to desalting and dialysis (Pierce). The purity of isolated
proteins was examined by SDS-PAGE. The identity of the isolated recombinant proteins
was confirmed by Western blot analyses using mouse anti-His (Sigma, 1:1000) and goat
anti-SPARC (R&D Systems, 1:1000) antibodies.

3-9. ELISA Protein Binding Assays
For direct ELISA binding assays, 20 lg/ml of collagen I (Cultrex, Gaithersburg,
MD), collagen IV (Cultrex), or fibronectin (BD Bioscience) was immobilized onto 96-well
Maxisorb Immunoplates (NUNC) overnight at 4oC, respectively, by absorption. The coated
plates were washed with PBS/0.01% Triton-X (PBST), followed by blocking with 3%
bovine serum albumin (BSA) at room temperature for 2 hours. Full length (FL)-SPARC,
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C-SPARC, N-SPARC, and a control His6-tagged protein CLIC4 (Daquinag et al., 2011)
were biotinylated (Thermo Scientific) and 100 nM of proteins was added and allowed to
bind for 2 hours at room temperature (Fig. 4-7A). Similarly, direct ELISA binding assay
was also performed with SPARC protein immobilized onto 96-well followed by washes,
blocking, and treatment with biotinylated 51 integrin (R&D Systems, 1.25 g/ml) (Fig.
4-5G). For competitive ELISA binding assays (Fig. 4-7B), the ECM-coated plates were
washed with PBST, followed by blocking with 3% BSA. Biotinylated mouse 51 or
11 integrin (R&D Systems, 1.25 mg/ml) was pretreated with 100 nM of His6-tagged
SPARC, C-SPARC, N-SPARC, or CLIC4 then allowed to bind to the ECM-coated wells.
Bound biotinylated proteins were probed with streptavidin-HRP (R&D Systems, 1:200)
after three washes with PBST. Ultra-TMB (Pierce) substrate was added, and absorbance
was measured at 450 nm using a SpectraMax M2 (Molecular Devices, Sunnyvale, CA).

3-10. Cell adhesion and detachment assay
Cell adhesion assay was performed as described (Humphries, 2009) with minor
modifications. Briefly, 96-well plates were coated with 20 g/ml fibronectin (BD
Bioscience) overnight at 48C and blocked with 10 mg/ml of heat-denatured BSA for 30
minutes at room temperature.Passage-1 SPARC-/- ASC were trypsinized and resuspended
in warm DMEM/HEPES (gassed with 5% CO2) at a concentration of 5x105 cells per
milliliter followed by 10 minutes incubation at 37 oC. Fifty milliliters of cell suspension
was mixed with FL-SPARC or SPARC isoforms (500 nM) and plated onto the fibronectincoated plates in triplicates. Cells were incubated at 37 oC and at the 15 minutes time point,
phase-contrast images were captured. After 1 hour incubation, wells were washed with
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PBS, fixed with paraformaldehyde, and stained with crystal violet. For quantification, the
percentage of cells with rounded morphology was scored by analyzing 10 representative
x10 view fields. Cell detachment assay was performed with passage-1 SPARC-/- ASC or
3T3L1 transduced with non-targeted shRNA or shRNA silencing b1 integrin, ILK, or FAK
that were plated onto fibronectin-coated 96-well plate. 500 nM of FLSPARC, C-SPARC,
or N-SPARC was added to ASC (for indicated time interval) or 3T3L1 control knockdown
or protein silenced clones (for 30 minutes). The dislodged cells were aspirated and wells
were washed with PBS. Remaining cells were fixed with 10% paraformaldehyde for 10
minutes at room temperature followed by washing and crystal violet staining/microscopy.
For quantification, cells in 10 x10 view fields were counted or crystal violet stain was
dissolved with 10% acetic acid and cell number was read as absorbance (570 nm). The
percentage of adherent cells was measured by normalizing to OD of untreated control
wells.
Statistical Analyses
Microsoft Excel was used to graph data as mean ± SEM and to calculate P-values using
homoscedastic Student’s t-Test. P < 0.05 was considered significant. Data met
assumptions of normality.
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Chapter 4
Results

Figures 4-1 to 4-2 are obtained and modified by permission from the American
Association for Cancer Research: Yan Zhang, Alexes C. Daquinag, Felipe AmayaManzanares, Olga Sirin, Chieh Tseng, and Mikhail G. Kolonin. Stromal Progenitor Cells
from Endogenous Adipose Tissue Contribute to Pericytes and Adipocytes That Populate
the Tumor Microenvironment. Cancer Research, 2012, 72(20), 5198-5208. And Figures 43 to 4-14 are obtained by permission from Stem Cells: Chieh Tseng and Kolonin,
Proteolytic Isoforms of SPARC Induce Adipose Stromal Cell Mobilization in Obesity,
Stem Cells, Epub ahead of print.
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SUMMARY

B

F

Obesity increases cancer risk and progression as shown by epidemiologic studies.
However, the underlying pathophysiology remains unclear. In this study, we show that the
ASC pool is expanded in obesity and is associated with promoting of tumor growth. Next,
by using a chimeric GFP-RFP bone marrow transplant model, we observed higher numbers
of tumor-infiltrating cells with ASC phenotype in tumor grafted in obese mice compared to
lean. Consistently, systemic circulating ASC frequency is six fold higher in tumor-bearing
obese mice compared to lean. The tumor infiltrating cells with ASC phenotype are found
to be perivascular, suggesting that there are being incorporated into vessels as pericytes to
support tumor vasculature. We have obtained evidence that ASC are mobilized in response
to obesity and cancer; however, the mechanisms regulating ASC trafficking are poorly
defined. Previously, we reported the binding of the matricellular protein SPARC to β1
integrin on ASC surface induces their motility (Nie et al., 2008). However, the
physiological significance of this SPARC effect has not been established. Here, for the first
time, we report that SPARC is required for ASC mobilization in obesity and investigate the
biochemical mechanism of its function. We show that SPARC is required for ASC
mobilization into the systemic circulation in obesity. We also identified the mechanism of
signal transduction induced by SPARC binding to its receptor, β1 integrin, on ASC surface.
Our result demonstrates that this interaction induces ASC motility through integrindependent FAK-ERK signaling and integrin independent ILK-Akt signaling. We further
identified two SPARC proteolytic isoforms, CSPARC (lacking the N-terminus) and NSPARC (lacking the C-terminus), generated in visceral WAT in the context of obesity. We
show that C-SPARC, but not N-SPARC, binds to β1 integrin on ASC, while N-SPARC
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preferentially binds to the ECM and blocks ECM/integrin interaction. Our study
demonstrates that that both C-SPARC and N-SPARC induce ASC de-adhesion from the
ECM, which is associated with modulation of integrin-dependent FAK-MAPK signaling
and integrin-independent ILK-Akt signaling. Importantly, we show that these SPARC
isoforms, acting on ASC through distinct mechanisms, have an additive effect in inducing
ASC migration.
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RESULTS
Obesity-induced promoted tumor growth independent of diet
Obesity promotes tumor growth, which has been demonstrated by multiple groups
(Allott and Hursting, 2015; Calle and Kaaks, 2004; Calle et al., 2003). In our study, we set
up cohort of obese (body weight greater than 45 grams) and lean mice (body weight less
than 30 grams) by placing them on high-fat diet or low-fat diet. To eliminate the difference
in diet as confounding variables in cancer progression, diet normalization was initiated by
subjecting both groups of mice to regular chow for 1 month before tumor engraftment.
Consistent with previous studies, Lewis lung carcinoma (LLC) growth engrafted in obese
mice exhibited accelerated growth kinetics as compared to the lean mice (Fig. 4-1A). A
concomitant reduction in body weight was observed in obese mice as tumors grew in size;
however, the lean mice weight remained relatively constant throughout (Fig. 4-1A). Our
data suggest that the excessive WAT in obesity is a crucial component in obesity-induced
tumor growth. In obese mice, a 7-fold increase in WAT mass was observed (data not
shown). As WAT is characterized by abundance of ASC, we next evaluated the effect of
increased adiposity on ASC frequency. ASC frequency was measured by enumerating
CD34+CD31-CD45- expressing cells with flow cytometry (Zhang et al., 2009). Our result
showed modest elevation in ASC frequency in obese mice intraperitoneal (i.p.) WAT
measuring 32.6 % whereas in lean mice, a 30.4% was detected. Given the WAT mass was
expanded in obesity, with a total of 1.0 ± 0.23 grams in lean and 6.19  0.25 grams from
obese mice i.p. WAT. The net number of ASC from obese mice was extrapolated to be 6
times higher in obese mice as compared to lean mice (Fig. 4-1C). Taking advantage of
plastic-adhering properties of ASC, we subjected the WAT stromal/vascular cells fraction
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to culture. We quantified and recovered a higher number of ASC from obese mice (Fig. 41E), characterized by defined nuclei and nucleoli (white arrow) distinct from Indian ink
internalizing monocytic cells (black arrow) (Fig. 4-1D). Together, these data demonstrated
that the expanded WAT mass in obesity act as additional ASC reserve. We next set out to
test if the increased ASC reserve contributes to cancer progression by facilitating ASC
trafficking into systemic circulation and recruitment to tumors. We analyzed circulating
ASC frequency of tumor-bearing obese and lean mice, by comparing CD34+CD45- cell in
PBMC. The result showed limited frequency of circulating CD34+CD45-cells (0.06%) in
lean mice, while in obese mice, a 6-fold increase in frequency was registered (to 0.37%)
(Fig. 4-1F). Morphologic analysis of FACS sorted-cell expressing CD34+CD31-CD45from PBMC or WAT, revealed them to be similar and undistinguishable from one another
(Fig. 4-1G). PBMC-derived CD34+CD31-CD45- cells from obese mice formed
fibroblastoid colonies with adipogenic potential, characterized by lipid-containing
adipocytes (Fig. 4-1H). Combined, our data showed increased obesity-associated egress of
CD34+CD31-CD45- adipose tissue-derived progenitors in circulation with ASC phenotype.
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Figure 4-1: ASC expansion promotes tumor growth

(A) LLC tumor growth kinetic in diet-induced lean and obese C57BL/6 mice. Following
diet normalization (week 0), LLC were engrafted onto lean and obese C57BL/6 mice (left).
Body mass of mice following tumor engraftment (right). Error bars, SEM. *, P < 0.05.

(B) Flow cytometric analysis of ASC in i.p. WAT (shown as percentage of viable cells).
Viable SVF were gated for CD31-CD45- cells and subsequently on CD34+ cells. SSC-A,
side scatter. (C) Relative ASC number in i.p.WAT of lean and obese mice. Quantification
based on CD34+CD31-CD45- ASC frequency enumerated by flow cytometry and total i.p.
WAT mass recovered from lean and obese mice. (D) Representative bright field
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micrograph of Indian ink-stained i.p.WAT cells cultured for a day. ASC (white arrowheads)
and monocytes (black arrows). (E) Relative adherent ASC number recovered from
i.p.WAT of lean and obese. Scale bar, 50 mm. Error bars, SEM. *, P < 0.05.

(F) Flow cytometry enumeration of CD34+CD31-CD45- cells from PBMC of lean and
obese mice with tumor, shown as percentage of viable cells. (G) Representative phase
contrast micrographs of FACS-sorted cells from WAT or PBMC (CD34+CD31-CD45-) of
an obese mouse. (H) Micrographs of PBMC–derived CD34+CD31-CD45- stained with Oil
red O, showing lipid droplets (white arrows).
Experiments in figure 4-1 were conducted by Yan Zhang, Felipe Amaya-Manzanares, Olga
Sirin and Chieh Tseng.
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Bone marrow transplantation model for tracking WAT-derived cells
Next, to test whether excessive WAT contributes to circulating ASC, we designed
an in vivo model to enable us to distinguish ASC from cells of hematopoietic origin
(Chantrain et al., 2008; Du et al., 2008; Kolonin et al., 2012). The chimeric GFP-RFP bone
marrow transplant model was generated by replacing irradiated GFP-mouse bone marrow
with RFP cells. Both GFP+ and RFP+ cells were found in all tissues evaluated and we
have confirmed RFP+ cells to co-express CD45+ leukocyte markers.
Similar to the no color mice, chimeric GFP-RFP mice placed on HFD or LFD were
normalized to the regular chow diet prior to EO771 tumor engraftment. Tumor growth and
volume were significantly greater in obese chimeric GFP-RFP. Consistently, higher GFP+
infiltrating cell numbers with ASC phenotype were recovered from tumors of obese
chimeric mice. Our result demonstrates a higher ASC trafficking from WAT to tumor in
obesity.
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4-2. Pericyte recruitment in obesity and tumor vascularization

To determine the functional roles of recruited ASC in tumor, we evaluated the
difference in tumor structures between lean and obese mice. Haematoxylin eosin staining
of tumor revealed increased malignant cells viability with reduced hemorrhagic and
necrotic regions in obese mice. On the basis that angiogenesis is a key determinant in
tumor growth that is crucial in providing oxygenation, nutrient delivery and waste removal
(Du et al., 2008; Hanahan and Weinberg, 2011). We therefore assessed whether ASC
infiltrating into tumor is associated with angiogenesis and blood vessel remodeling.
Comparative immunofluorescence analysis of tumor sections demonstrated that a higher
number of host-derived GFP+ cells reside in close proximity with CD31+ endothelial cells
in tumors of obese mice (Fig. 4-2A and 4-2B). The co-localization of GFP+ cells with
pericyte marker: desmin, revealed them to be involved in tumor vessels maturation.
Notably, in obese mice, the tumor vasculature density was 2-fold higher than the lean mice.
(Fig. 4-2C). Tumor blood vessels in lean mice were found sparsely distributed and
structurally more compressed, whereas in obese mice, the tumor vasculature was larger and
better perfused with blood cells (Fig. 4-2A and 4-2B). Quantification of blood vessels coexpressing desmin and GFP in tumors showed a higher frequency in the obese mice (Fig.
4-2D), suggesting increased vessel maturation associated with obesity (Fig. 4-2C).
Combined, these results reinforce the notion that ASC expansion in obesity contributes to
the perivascular cell pool, thereby promoting tumor progression.
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4-2. Pericyte recruitment in obesity and tumor vascularization

(A & B) Representative immunofluorescence images of tumor section from obese and lean
mice stained with antibodies against CD31 (red) and GFP (green). Images shown were
taken at high (B) and low (A) magnification of tumor internal viable regions. Tumor
vessels contains GFP+CD31- perivascular/stromal cells indicated by green arrows and
luminal GFP+CD31+ endothelial cells (yellow arrows) and. Note increased pericyte
coverage and larger in size of the tumor vessels in obese mice.
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(C) Comparative analysis of tumor vessel density, width and pericytes coverage between
obese and lean. Vessel density was quantified as mean number of vessels/100x view field.
Vascular size was assessed as mean lumen width for all vessels scored. The maturity of
vessel was assessed as mean percentage of vessels associated with desmin+ pericytes
among all vessels scored. Error bar, SEM. D, confocal immunofluorescence tumor analysis
with antibodies against GFP (green) and desmin (red). Yellow signal indicates GFP+
pericytes, which is confirmed by Z-stack projections of median series for individual cells
in the indicated magnified area (bottom).
Experiments in figure 4-2 were conducted by Yan Zhang, Felipe Amaya-Manzanares and
Chieh Tseng.
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4-3. SPARC Promotes Mouse ASC Motility and Mobilization
Having shown that ASC are mobilized in cancer and obesity (Zhang et al., 2012)
and our observations that SPARC induces ASC de-adhesion and motility (Nie et al., 2008),
we hypothesized that SPARC promotes ASC mobilization. To test this in vivo, we
compared ASC circulation in SPARC-/- mice (Bradshaw et al., 2003a; Norose et al., 1998)
and wild-type (WT) SPARC+/+ mice. Peripheral blood mononuclear cells (PBMC) were
analyzed in lean mice (<30 g) raised on chow and in diet-induced obese (DIO) mice (>45 g)
raised on high-fat diet for 5 months. Circulating ASC among PBMC were enumerated by
flow cytometry based on the previously established CD34+CD31-CD45- cell surface
signature and gating strategy (Daquinag et al., 2015; Daquinag et al., 2011; Zhang et al.,
2012). Only background (0.01%) of PBMC had the ASC immunophenotype in lean mice,
while upon DIO induction 0.12% of PBMC were registered as ASC (Fig. 4-3A). In
contrast, only background (0.015% of PBMC) ASC circulation was observed in obese
SPARC-/- mice, while the frequency of CD45+ leukocytes was unaffected by SPARC
deficiency.
We then explored the mechanism through which SPARC may induce cell mobilization.
Our previous analysis of human SPARC effect on ASC motility was potentially
confounded by secretion of endogenous SPARC by ASC (Nie et al., 2008). Here, based on
a reported approach (Bradshaw et al., 1999), we used cells from SPARC-/- mice to avoid
interference by autocrine secretion of SPARC. In a trans-well assay, recombinant mouse
SPARC protein added to the cell culture medium promoted migration of suspended murine
ASC in a dose-dependent manner (Fig. 4-3B). To assess the effect of SPARC on adherent
ASC, we examined the response of ASC cultured on plates coated with fibronectin, an
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adhesion ligand of α5β1 integrin. After 10 minutes of incubation with SPARC, the
majority of ASC exhibited a rounded morphology and after 12 hours underwent partial
detachment, while untreated ASC remained well spread (Fig. 4-3C). These results
suggested that SPARC induces ASC mobilization by promoting their de-adhesion from the
matrix.
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4-3 SPARC promotes ASC mobilization and migration

(A) SPARC is required for ASC mobilization. Viable PBMC stained with CD45-APC-cy7,
CD31-PE and CD34-eFluor 660 were gated based on isotype controls to identify ASC as
CD34+CD31-CD45- cells. The graphs show relative percentage of ASC in PBMC of lean
and obese WT and SPARC-/- mice (n=3/group).
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4-3. SPARC promotes ASC mobilization and migration

(B) SPARC promotes ASC motility. Primary ASC from SPARC-/- mice were incubated
without (-) or with indicated concentrations of mouse recombinant SPARC and allowed to
trans-migrate through 8 m pores within 16 hrs and stained with crystal violet.
Representative micrographs are shown. Mean numbers of trans-migrated cells / view field
at indicated SPARC concentration are quantified in the graph.

(C) SPARC induces ASC de-adhesion. Phase-contrast images of SPARC-/- ASC on
fibronectin-coated plate were taken at 10 min and 12 hrs after exposure to 25 g/ml (735
nM) SPARC. Normalized percentage of adherent cells at indicated time point is quantified
in the graph. Experiments shown were repeated at least three times with similar result.
Scale bar, 50 µm. Error bars, SEM from triplicate wells. * P0.05.
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4-4. SPARC-induced ASC deadhesion is linked with 1 integrin signaling
Based on previous studies suggesting that SPARC promotes cell motility by
binding to β1 integrin at focal adhesions (Nie et al., 2008; Weaver et al., 2008), we further
investigated the signaling events activated by this protein interaction. SPARC-/- ASC
treated with mouse SPARC, which induced a time-dependent change in cell morphology
evident by bright-field microscopy (Fig. 4-4A), were subjected to immunofluorescence
analysis. An antibody against phosphorylated (Tyr118) paxillin demonstrated that focal
adhesions observed in untreated cells became disassembled upon SPARC treatment (Fig.
4-4A). This was concomitant with active 1 integrin changing its localization from the cell
surface to the peri-nuclear area, as revealed with an antibody specifically binding to active
1 integrin (Fig. 4-4A). This integrin redistribution, indicative of integrin internalization
and recycling typically observed upon stimulation of cell migration (Gu et al., 2011), was
associated with a marked cytoskeleton reorganization revealed by F-actin staining with
phallodin (Fig. 4-4A).
Our previous work showed that 3T3-L1 preadipocytes serve as a convenient model to
study SPARC / 1 integrin interaction (Nie et al., 2008). The response of 3T3-L1 cells to
SPARC was similar to that of SPARC-/- ASC, albeit less striking (Fig. 4-4B). This
indicated that endogenous SPARC, which is produced by 3T3-L1 cells (Chavey et al.,
2006), does not preclude the effect of exogenous SPARC. To determine whether 1
integrin, ILK, or FAK are essential for SPARC signaling, we individually silenced each of
these genes in 3T3-L1 cells using lentivirus expressing targeted short hairpin RNAs
(shRNA); 3T3-L1 cells transduced with a non-targeted shRNA were used as control. For
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each gene, we tested several clones and chose a representative clone displaying expression
silencing of the respective protein, as verified by immunoblotting (Fig. 4-4C). We serumstarved the cells and examined the effect of SPARC on signaling after 5 and 15 min. FAK
phosphorylation was substantial in control untreated cells, while treatment with SPARC
reduced FAK phosphorylation at Tyr397 in a time-dependent manner (Fig. 4-4C). Tyr397
is a site of FAK autophosphorylation, reduction in which is observed upon a decrease in
integrin signaling (Caswell and Norman, 2006; Eke et al., 2012; Lu et al., 2001; Zheng and
Lu, 2009). Concomitantly, increased Thr202/Tyr204 phosphorylation of ERK1/2 was
observed for SPARC-treated cells (Fig. 4-4C). Baseline FAK phosphorylation in the
absence of SPARC was decreased for both 1 integrin knockdown and ILK knockdown
cells (Fig. 4-4C). The changes in FAK and ERK1/2 phosphorylation upon SPARC
treatment were not observed in cells with silenced 1 integrin, ILK, or FAK. These data
indicate that MAPK activation by SPARC relies on 1 integrin signaling through both ILK
and FAK (Fig. 4-4C). Because SPARC signaling is mediated by protein kinase B (Akt) in
cancer cells (Alachkar et al., 2014; Shi et al., 2007), we also analyzed Akt activation. Akt
phosphorylation (S473) was modestly induced by SPARC not only in control but also in
1 integrin, ILK, and FAK knockdown cells (Fig. 4-4C). This suggests that Akt activation
in SPARC-treated cells is likely a non-specific response to cell de-adhesion rather than due
to 1 integrin signaling.
Loss of either 1 integrin, FAK, or ILK resulted in abrogation of SPARC-induced
induction of suspended cell motility (Fig. 4-4D). We also observed a reduction in SPARCmediated cell de-adhesion in the absence of 1 integrin, FAK, or ILK (Fig. 4-4E).
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Combined, these results indicate that SPARC-mediated cell de-adhesion and migration is
associated with inhibition of 1 integrin signaling through ILK and FAK.
4-4. SPARC-induced ASC deadhesion is linked with 1 integrin signaling

(A) Representative phase-contrast images of SPARC-/- ASC on fibronectin-coated plates
incubated with 500 nM of FL-SPARC for indicated periods of time. Immunofluorescence
with antibodies against activated 1 integrin (arrow) costained with p-paxillin (Tyr118)
antibodies, SPARC antibodies, or phalloidin revealing cytoskeletal filaments is shown.
Nuclei are blue.
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4-4. SPARC-induced ASC deadhesion is linked with 1 integrin signaling

(B) SPARC-induced 3T3L1 de-adhesion is linked with β1 integrin signaling.
Representative phase-contrast images of 3T3L1 on fibronectin-coated plates incubated with
500 nM of FL-SPARC for 0, 5 and 15 min time interval. Immunofluorescence with
antibodies against activated β1 integrin (arrow) co stained with p-paxillin (Tyr118),
SPARC and phalloidin revealing cytoskeletal filaments is presented. Nuclei are blue. Scale
bar, 50 µm.
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4-4. SPARC-induced ASC deadhesion is linked with 1 integrin signaling

(C) 3T3-L1 cells were transduced with non-targeted shRNA (control) or shRNA silencing
1 integrin, ILK, or FAK. Serum-starved cells were incubated with mouse SPARC (500
nM) and cell lysates obtained at 0, 5, and 15 minutes post treatment were analyzed by
Western blotting using antibodies against indicated antigens. Anti--actin immunoblotting
demonstrates equal protein loading for different time points.
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4-4. SPARC-induced ASC deadhesion is linked with 1 integrin signaling

(D) Dose-dependent trans-well migration of 3T3-L1 cells transduced with non-targeted
shRNA or shRNA silencing 1 integrin, ILK, or FAK. For the assay, cells were exposed to
SPARC at indicated concentrations.

(E) Cell detachment assay with 3T3-L1 cells transduced with non-targeted shRNA or
shRNA silencing b1 integrin, ILK, or FAK incubated with 500 nM SPARC for 30 minutes.
Data shown are representative of two or three independent experiments. Error bars, SEM
from triplicate wells. *, p<0.05.
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4-5. Obesity-induced SPARC isoforms in MS WAT
To identify the source of ASC mobilized in obesity, we investigated the differences
in SPARC expression in individual WAT depots of lean and DIO mice.
Immunofluorescence analysis revealed high expression of SPARC protein in mesenteric
(MS) WAT of DIO mice (Fig. 4-5A). Distribution is very different while in WAT of lean
mice SPARC was observed mainly in stromal cells; in DIO mice SPARC was also
abundant in adipocytes (Fig. 4-5A). To quantify this change, protein extracts from MS,
subcutaneous (SC), and epididymal (EP) WAT from lean and obese mice were
immunoblotted with SPARC antibodies. This confirmed the highest (5.5-fold) induction in
SPARC levels for MS WAT in obesity, while less than a 2-fold obesity-associated
elevation was observed for SC and EP WAT after normalization to -actin expression (Fig.
4-5B).
We next investigated if obesity results in generation of SPARC isoforms.
Immunoprecipitation from distinct WAT depots was performed using an antibody mab303
that recognizes an epitope R149-L198 within the EC domain of SPARC (Weaver et al.,
2008). Immunoblotting with polyclonal anti-SPARC antibodies demonstrated the presence
of a lower molecular weight obesity-specific SPARC isoform in MS WAT (Fig. 4-5C).
Scaled-up immunoprecipitate separated on a protein gel revealed the presence of an
additional SPARC isoform generated in MS WAT of obese mice (Fig. 4-5D).
Densitometry quantification of protein bands revealed that the abundance of full length
(FL)-SPARC: C-SPARC: N-SPARC was 2.3: 1.3: 1.0, respectively, in MS WAT. The two
MS WAT obesity-specific SPARC isoforms were subjected to Edman degradation protein
sequencing, which identified them as proteolytic fragments of SPARC. The longer
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fragment (amino acids 14-285) missing the 13 N-terminal residues was termed C-SPARC;
the shorter fragment (amino acids 1-196) missing amino acids (197-285) was termed NSPARC (Fig. 4-5E). According to previous SPARC domain mapping (Hohenester et al.,
2008; Kzhyshkowska et al., 2006; Nie et al., 2008; Sasaki et al., 1998; Weaver et al., 2008),
C-SPARC is expected to bind to 1 integrin, while N-SPARC, lacking the C-terminal 1
integrin-binding domain, is expected to be deficient in integrin binding but still bind to
stabilin-1.
To analyze the function of SPARC proteolytic isoforms, we constructed vectors for
expression of FL-SPARC, C-SPARC, and N-SPARC as fusions with a His6 tag. To ensure
glycosylation and functionality of the secreted proteins, mammalian HEK293 cells were
stably transfected with the expression vectors or insertless vector control. His6-tagged FLSPARC, C-SPARC, and N-SPARC were affinity-purified from conditioned media
collected from transfection clones. Identity, purity, and concentration normalization of the
soluble recombinant proteins was performed by immunoblotting with anti-SPARC
antibodies (Fig. 4-5F). To test whether N-SPARC retains  integrin interaction, we
precipitated protein complexes from cells co-transfected with 1 integrin and indicated
SPARC

variants

with

anti-His

tag

antibodies

and

immunoblotted

the

co-

immunoprecipitates with anti-1 integrin antibodies. As expected, 1 integrin coimmunoprecipitated with FL-SPARC and C-SPARC, while its co-immunoprecipitation
with N-SPARC was markedly lower (Fig. 4-5F). We further validated our observation by
assessing direct binding of biotinylated 51 integrin to SPARC variants. While FLSPARC and C-SPARC displayed direct 51 integrin binding, N-SPARC binding was not
significantly above nonspecific background (Fig. 4-5G). These data confirm that the
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SPARC C-terminus mediates 1 integrin binding and suggest that the C-SPARC and NSPARC isoforms may have distinct functions.
4-5. Obesity-induced SPARC isoforms in MS WAT

(A) Immunofluorescence analysis of MS WAT sections from lean and obese mice with
anti-SPARC (green), anti-perilipin (red) antibodies. Nuclei are blue.

(B) Tissue lysates obtained from SC, MS, and EP WAT of WT lean and obese mice were
analyzed for SPARC expression by Western blotting. Densitometry values were adjusted

70

to -actin intensity and expression above level observed in SC WAT of lean mice was
calculated (ratio) with AlphEaseFC software.

(C) Tissue lysates obtained from distinct WAT depots of lean and obese mice were IP with
a SPARC monoclonal antibody Mab303. Non-immune IgG IP from obese MS WAT
extracts served as a negative control. A single full-length (FL)-SPARC protein band at 43
kDa is present for SC, MS, and EP WAT of WT but not SPARC-/- mice. Arrow: additional
39 kDa C-SPARC band immunoprecipitated from obese MS WAT. Light chain IgG
recognized by the secondary antibody demonstrates equal protein loading.

(D)

For

indicated

WAT

depots,

scale-up

Mab303

immunoprecipitation

and

immunoblotting was performed as in (C) Shown is Coomassie blue staining of the PVDF
membrane prepared for Edman degradation sequencing that identified two indicated bands
as C-SPARC and N-SPARC (arrows). (E) A schematic map of reported protein binding
domains on FL-SPARC and sites of proteolytic cleave (arrows) giving rise to C-SPARC
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and N-SPARC. Edman degradation sequence terminal are numbered in the SPARC
sequence, most of which is abbreviated (–). Acidic, FS-like, and EC domains of SPARC
are indicated. Abbreviations: ASC, adipose stromal cells; ECM, extracellular matrix; EP,
epididymal; IP, immunoprecipitated; MS, mesenteric; SC, subcutaneous; SPARC, secreted
protein acidic and rich in cysteine; WAT, white adipose tissue; WCE, whole cell extract;
WT, wild type.

(F) Whole cell extracts from HEK293T of 1 integrin co-transfected with His6-tagged FLSPARC, C-SPARC, N-SPARC, or control vector were immunoprecipitated with anti-His
tag antibody, and immunoprecipitates were immunoblotted with 1 integrin and SPARC
antibodies, which shows preferential FL-SPARC and C-SPARC integrin binding.
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(G) Wells coated with FL-SPARC, C-SPARC, N-SPARC, or control protein were
incubated with 1.25 mg/ml of biotinylated 51 integrin. Mean protein binding was
measured with a secondary streptavidin-HRP conjugate and calorimetric spectroscopy
(OD450), which shows preferential FL-SPARC and C-SPARC integrin binding.
Representative data shown are from experiments repeated three (B–D, G) or two (F) times.
Error bars, SEM from triplicate wells. *, p<0.05 versus His control. Scale bar 50 m.
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4-6. C-SPARC, but not N-SPARC, binds to ASC
Because SPARC binds to ASC as a ligand of 1 integrin, we predicted that NSPARC lacking the integrin interaction domain might have reduced binding to ASC. To
test this hypothesis, SPARC-/- ASC were incubated with FL-SPARC, C-SPARC, or NSPARC in the medium, washed, and subjected to immunofluorescence analysis with
polyclonal anti-SPARC antibodies that recognize all SPARC isoforms. Our data show that
FL-SPARC and C-SPARC bind to ASC surface, while N-SPARC does not (Fig. 4-6A). To
quantify binding differences, we immunoblotted protein extracts from ASC after SPARC
isoform addition at several time points. This result indicated that the kinetics of FLSPARC and C-SPARC to ASC is comparable, while N-SPARC completely lacks the
capacity to bind ASC (Fig. 4-6B).
To further assess selectivity of FL-SPARC, C-SPARC, and N-SPARC for distinct cell
types, we exposed partly enzymatically-digested fragments of WAT from SPARC-/- mice to
the His-tagged SPARC fragments. Upon washing and fixation, whole mounts were
subjected to immunofluorescence (Fig. 4-6C). Counterstaining with isolectin B4 (IB4),
which specifically binds to the endothelium, demonstrated that all three recombinant
proteins bound to stromal cells. FL-SPARC and C-SPARC binding was localized to ASC,
identified as perivascular cells negative for IB4 and CD45 (data not shown) and positive
for CD34, as well as to alternatively activated macrophages, identified as IB4- cells
positive for F4/80 and stabilin-1 (Fig. 4-6C). In contrast, N-SPARC bound exclusively to
IB4- / F4/80+ / stabilin-1+ macrophages but not to IB4- / CD34+ ASC (Fig. 4-6C). These
results indicate that FL-SPARC and C-SPARC bind to both ASC and macrophages, while
N-SPARC lacking the integrin-binding domain is only capable of binding to macrophages.
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4-6 C-SPARC but not N-SPARC binds to ASC

(A) Adherent SPARC-/- ASC were incubated with 100 nM of indicated recombinant His6tagged SPARC isoforms or control vector in serum-free medium for 10 min.
Immunofluorescence with anti-SPARC antibody (green) reveals that FL-SPARC and CSPARC, but not N-SPARC, bind to ASC. (B): Anti-SPARC immunoblotting of protein
extracts from ASC treated as in (A) for indicated time intervals. Anti-β-actin
immunoblotting demonstrates equal protein loading.
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4-6 C-SPARC but not N-SPARC binds to ASC

(C) Partly enzymatically digested fragments of MS WAT from SPARC-/- mice were treated
with 100 nM of FL-SPARC, C-SPARC, or N-SPARC for 30 min, washed, and then fixed
whole mounts were subjected to immunofluorescence with antibodies against the indicated
antigens. Endothelium is stained with isolectin B4 (IB4). Green arrows point to SPARC
isoform on antigen-negative cells; yellow co-localization signal reveals that C-SPARC
binds to CD34+ ASC and to F4/80+ and stabilin-1+ macrophages, while N-SPARC binds
only to F4/80+ / stabilin-1+ macrophages. Representative data shown are from
experiments repeated three times. Nuclei are blue. Scale bar, 50 µm.
76

4-7 N-SPARC is a potent extracellular matrix (ECM) binder and integrin/ECM blocker
Because N-SPARC retains its ECM-binding domain, we investigated the effect of
this isoform on integrin / ECM interaction. First, we compared the binding of biotinylated
recombinant SPARC variants to fibronectin and collagen I. N-SPARC displayed a slightly
higher binding to these ECM molecules than FL-SPARC at higher concentrations, while
C-SPARC binding was decreased (Fig. 4-7A). Binding of FL-SPARC to collagen was
competed by N-SPARC (data not shown), confirming the retention of ECM-binding site in
this isoform. Because N-SPARC binds ECM but does not bind to 1 integrin, we predicted
that it may have the capacity to block integrin / ECM interaction. To assess that, we
compared the effects of the SPARC isoforms in a competitive ELISA assay. Biotinylated
51 integrin was pre-incubated with the recombinant SPARC proteins and its binding to
fibronectin was quantified. Compared to FL-SPARC and C-SPARC, N-SPARC
demonstrated a higher capacity to block 51 integrin binding to fibronectin (Fig. 4-7B).
N-SPARC also blocked 11 integrin / collagen I binding more efficiently than FLSPARC and C-SPARC (Fig. 4-7B). These results suggest that N-SPARC has an increased
capacity to inhibit ASC adhesion to the ECM.
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4-.7 N-SPARC is a potent extracellular matrix (ECM) binder and integrin interaction
blocker

(A) ECM molecule-coated wells were incubated with biotinylated recombinant His6tagged FL-SPARC, C-SPARC, N-SPARC or control protein at indicated concentrations.
Mean protein binding was measured with a secondary streptavidin-HRP conjugate and
calorimetric spectroscopy (OD450).
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4-7. N-SPARC is a potent extracellular matrix (ECM) binder and integrin interaction
blocker

(B) Biotinylated α5β1 or α1β1 integrin were pre-incubated with 100 nM recombinant
His6-tagged FL-SPARC, C-SPARC, N-SPARC or control protein. Wells, which were
ECM molecule-coated as in (A), were incubated with the pretreated biotinylated α5β1 or
α1β1 integrin at indicated concentrations. Mean biotinylated protein binding was measured
with secondary streptavidin-HRP conjugates and calorimetric spectroscopy (OD450).
Representative data shown are from experiments repeated twice with triplicate wells. Error
bars, SEM from triplicate wells.
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4-8. Both C-SPARC and N-SPARC modulate 1 integrin signaling
The differences in ASC and ECM binding observed for N-SPARC and C-SPARC
suggested that these isoforms might differ in their capacity to activate 1 integrin signaling.
To test this hypothesis, we performed an experiment analogous to Figure 4-4C: 3T3-L1
cells expressing either a non-targeted shRNA (control cells) or shRNA silencing 1
integrin, ILK, or FAK were treated with N-SPARC and C-SPARC. Surprisingly, time
course immunoblotting analysis demonstrated that treatment with both C-SPARC and NSPARC still reduced Y397 FAK phosphorylation in a time-dependent manner in control
cells (Fig. 4-8A, B). Treatment with both C-SPARC and N-SPARC also transiently
increased Thr202/Tyr204 phosphorylation of ERK1/2 in control cells (Fig. 4-8A, B). As
seen with FL-SPARC, FAK autophosphorylation and ERK1/2 phosphorylation were not
affected in 1 integrin knockdown and ILK knockdown cells by either C-SPARC or NSPARC treatment (Fig. 4-8A, B).
We also compared the effect of proteolytic SPARC isoforms on ILK activity. Serumstarved 3T3L1 cells expressing either non-targeted shRNA or 1 integrin, ILK or FAK
silencing shRNA were incubated with FL-SPARC, C-SPARC or N-SPARC. After
incubation, proteins were immunoprecipitated with ILK antibodies and then incubated with
glycogen synthase kinase 3 (GSK-3), a model ILK substrate (Yokoyama et al., 2011). By
immunoblotting the kinase reactions with an anti-phospho-GSK-3 antibody, we found
that GSK-3 phosphorylation by ILK was promoted upon cell treatment with FL-SPARC,
C-SPARC, and N-SPARC in control cells (Fig. 4-8C). Residual ILK kinase activity was
also detectable in treated cells transduced with ILK shRNA, which can be explained by the
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observed ILK immunoprecipitation even despite its substantial silencing (Fig. 4-8C).
Interestingly, ILK kinase activity was still induced by FL-SPARC, C-SPARC and NSPARC upon 1 integrin or FAK silencing (Fig. 4-8C). These data from the 3T3-L1 model
were reproduced with immortalized mouse ASC (Zhang et al., 2009). Our results suggest
that SPARC-induced activation of ILK, as well as of Akt (Fig. 4-4C), is regulated by
signaling independent of 1 integrin and FAK.
4-8. Both C-SPARC and N-SPARC modulate 1 integrin signaling
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Both C-SPARC and N-SPARC modulate β1 integrin signaling. 3T3-L1 cells were
transduced with non-targeted shRNA (control) or shRNA silencing β1 integrin, ILK or
FAK. (A, B): Serum-starved cells were incubated with 500 nM His6-tagged C-SPARC (A)
or N-SPARC (B) and cell lysates obtained at 0, 5 and 15 min post-treatment were analyzed
by Western blotting using antibodies against indicated antigens.

Anti-β-actin

immunoblotting demonstrates equal protein loading for different time points.
4-8 Both C-SPARC and N-SPARC modulate 1 integrin signaling

(C) Serum-starved cells were untreated (No SPARC) or incubated with 500 nM His6tagged FL-SPARC, C-SPARC or N-SPARC for 10 min. Then cells were subjected to the
ILK kinase assay using GSK-3β as a substrate. Anti-p-GSK-3β immunoblotting signal
reflects the amount of active ILK immunoprecipitated. Anti-ILK immunoblotting
demonstrates reduced, yet measurable, ILK immunoprecipitation from cells transduced
with ILK shRNA. Representative data shown are from experiments repeated three times.
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4-9. Both C-SPARC and N-SPARC Induce ASC De-adhesion and cooperate in triggering
ASC migration
Because N-SPARC and C-SPARC have different binding target preferences but
have similar effect on cell signaling, we sought to compare their effects on cell attachment
to the ECM. To assess their effect on adherence, ASC in suspension were treated with
recombinant SPARC proteins and their ability to attach to fibronectin-coated plates was
evaluated. After 15 minutes, the majority of untreated ASC displayed spreading
morphology, whereas FL-SPARC, C-SPARC, and N-SPARC prevented fibronectininduced ASC attachment (Fig. 4-9A). We verified this result upon longer (1 hour) cell
observation (Fig. 4-9B). Compared to untreated control, treatment with FL-SPARC, CSPARC, and N-SPARC led to a comparable increase in the frequency of ASC with loosely
adherent morphology (Fig. 4-9B graph). We also compared the effect of recombinant
SPARC proteins on attached ASC grown on fibronectin-coated plates. Consistent with the
attachment data, the rounded cell phenotype indicating de-adhesion was induced not only
by FL-SPARC and C-SPARC, but also by N-SPARC treatment (Fig. 4-9C).
Finally, we compared the effects of recombinant SPARC isoforms on motility of
suspended serum-deprived ASC in a transwell assay. ASC trans-well migration was
induced not only by FL-SPARC but also by individual cleavage isoforms (Fig. 4-9D).
Because our data show that C-SPARC and N-SPARC are both generated in MS WAT and
induce ASC de-adhesion through distinct mechanisms, we hypothesized that they might
have additive effects. To test this hypothesis, we treated ASC from SPARC-/- mice with
combinations of recombinant SPARC isoforms at equimolar concentrations and quantified
the capacity of cells to migrate in the trans-well assay. The effect of FL-SPARC and C83

SPARC treatment alone on cell migration was comparable and more robust than that of NSPARC. Adding C-SPARC along with FL-SPARC did not further increase cell migration,
consistent with them acting through the same mechanism. Interestingly, combination of NSPARC and FL-SPARC had a reduced capacity in activating cell migration compared to
FL-SPARC alone. Importantly, while N-SPARC alone had a relatively modest effect on
cell motility, when it was added in combination with C-SPARC cell migration was
increased by 2-fold, compared to N-SPARC alone (Fig. 4-9D). The combination of CSPARC and N-SPARC was the only setting where cell migration induction was
significantly higher than by FL-SPARC alone. Combined, our data indicate that N-SPARC
and C-SPARC cooperate in detaching ASC from the ECM, which leads to their motility.
4-9. Both C-SPARC and N-SPARC induce ASC deadhesion and cooperate in
triggering ASC migration

(A) Phase contrast images of SPARC-/- ASC 15 min after plating on fibronectin-coated
plates in serum-free medium containing control (eluate from control vector), His6-tagged
FL-SPARC, C-SPARC, or N-SPARC (500 nM).
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(B) Crystal violet staining of SPARC-/- ASC 1 hr after plating on fibronectin-coated plates
in serum-free medium containing control, His6-tagged FL-SPARC, C-SPARC, or NSPARC (500 nM).

(C) SPARC-/- ASC pre-grown on fibronectin-coated plated were incubated with control,
His6-tagged FL-SPARC, C-SPARC, or N-SPARC (500 nM) for 1hr. Arrows: well
adherent cells, arrowheads: weekly adherent rounded cells. Graph shows the mean
percentage of rounded cells.
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(D) SPARC-/- ASC incubated with His6-tagged FL-SPARC, C-SPARC, or N-SPARC (500
nM) or their indicated equimolar admixes (combined concentration 500 nM) were
subjected to the trans-well assay. The graph shows the mean numbers of trans-migrated
cells/view field. Error bars, SEM from triplicate wells. P0.05 (* compared to untreated;
** compared to FL-SPARC).

A proposed model for the function of C-SPARC and N-SPARC in WAT. In lean mice,
adipocytes (not shown) express a basal level of FL-SPARC (RED: N-terminal domain;
GREEN: C-terminal domain). FL-SPARC binding to α5β1 integrin on ASC, as well as to
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the ECM and the basement membrane (BM) separating ASC and endothelial cells (EC),
maintains the dynamic equilibrium of ASC intermediate adhesion. In MS WAT of obese
mice, adipocytes express increased levels of FL-SPARC that undergoes proteolytic
processing resulting in N-SPARC and C-SPARC. N-SPARC blocks α5β1 integrin binding
to the ECM and the BM, while C-SPARC directly modulates β1 integrin signaling
favoring cell motility and survival. The additive effects of N-SPARC and C-SPARC
induce ASC de-adhesion and mobilization. Grey circles: nuclei. Representative data shown
are from experiments repeated at least twice with similar result.

A
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Chapter 5
Discussion & Conclusion
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5-1. Significance
Adipose stromal cells (ASC) are mesenchymal adipocyte progenitors abundant in
fat tissue. The increasing application of ASC in regenerative medicines has been reported
in multiple randomized clinical trials worldwide (Kolle et al., 2013; Lendeckel et al., 2004),
examining their efficacy across different areas including cardiovascular diseases,
autoimmune diseases, and plastic/reconstructive surgery. With ASCs’ vast potential for
clinical use, it is crucial to better understand their safety and mechanism involved in
regulating their mobilization.
Here, along with accumulating preclinical data (Park et al., 2011; Rowan et al., 2015;
Strong et al., 2015), we show that the ASC pool expands with obesity and contributes to
tumor growth by supporting tumor vasculature. We further evaluate the mechanism
involved in regulating ASC mobility. Extending our previous finding that the matricellular
protein SPARC binding to 1 integrin on ASC promoted its migration, we demonstrate the
physiological significance of SPARC in mobilizing ASC into the peripheral circulation.
We further identify novel proteolytic SPARC isoforms and demonstrate their involvement
in ASC migration. My thesis study contributes to unraveling the molecular mechanisms
involved in stem cell trafficking.
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DISCUSSION
It has been long believed that the systemic circulating adipokines are the main
pathophysiological connection between obesity and cancer (Calle and Kaaks, 2004).
Recently, the tumor-stimulating effect of cells recruited by tumors has been recognized.
Tumor growth/survival-promoting effects based on direct cellular contact and locally
secreted paracrine factors have been identified (Nieman et al., 2011; Zhang et al., 2009). In
our study, we tested the hypothesis of expanded adiposity in obesity, serving as a cell
source for tumor recruitment to support the tumor microenvironment. Here, we provide
evidence of ASC pool expansion in obesity and show an increased ASC in circulation.
Consistent with our model, a similar phenomenon is reported in patients with cancer
(Bellows et al., 2011; Mancuso et al., 2011). Concomitantly, higher frequency of ASC
recruitment in tumor engrafted in obese mice associates with increased pericytes coverage
and tumor growth. These findings are in accordance with pro-angiogenic effects of trophic
factors secreted by ASC (Gimble et al., 2007; Rehman et al., 2004). In sum, our data on
expanded ASC pool contributing to increased ASC recruitment to tumor caution against
the use of cell therapy in patients with cancer (Bertolini et al., 2012). Importantly, ASC
mobilization in cancer may be the functional determinant of their capacity to promote
cancer. This has prompted us to understand the mechanisms involved.
Chemotatic stimuli direct cell migration by inducing cell contraction and changes
in integrin clustering and attachment to the ECM. Integrin 1 is selectively overexpressed
on ASC is likely to control their migration. Previously, we reported that binding of
matricellular protein SPARC to integrin 1 on ASC induces migration. However, it
remains largely unknown what role SPARC plays in integrin signal transduction and to
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what extent its capacity to elicit cell detachment from ECM is due to modulating α5β1
signaling contributes to ASC mobilization (Legate et al., 2009). In our study, we
demonstrate that SPARC treatment induces focal adhesion disassembly in ASC,
hallmarked by decreased paxillin phosphorylation and rapid dephosphorylation of FAK at
Tyr397 which accompanied by integrin endocytosis (Nagano et al., 2012). Integrin β1–ECM
binding leads to integrin activation characterized by FAK autophosphorylation at Tyr397,
therefore, reduced FAK autophosphorylation at Tyr397 integrin is consistent with integrin
disengagement from ECM. Previously, SPARC signaling involving 1 integrin, FAK, ILK,
ERK and Akt had been evaluated in cancer cells (Shi et al., 2007; Shin et al., 2013). From
gene knockout experiments, we demonstrated that SPARC-mediated dephosphorylation of
FAK signaling is β1 integrin-dependent and is required for increased ERK1/2
phosphorylation on Thr202/Tyr204. This signaling cascade has been formerly demonstrated
as key in detachment and migration of epithelial cells (Lu et al., 2001; Teranishi et al.,
2009). Our data suggest that in stromal cells, this signaling pathway is also triggered by
SPARC. In addition, we show that SPARC induces ILK/Akt activation independent of the
1 integrin activity; we propose that it is non-specifically turned on in response to cell
detachment. In sum, our data show that SPARC disruption of integrin-engagement to ECM
and regulation of growth factor signaling.
Building on the earlier evidence of SPARC promoting ASC migration (Nie et al., 2008),
we show that SPARC activity is required for ASC mobilization. SPARC-deficient mice
exhibit impairment in ASC mobilization (Fig. 4-3A) and tumor engrafted onto SPARCdeficient mice present with increased permeability, reduced pericytes and lower
microvessel density (Arnold et al., 2010; Brekken et al., 2003), consistent with ASC’s role
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in protecting vessel patency.

Matricellular protein SPARC is a substrate for numerous extracellular proteases.
Cleavage of SPARC produces bioactive fragments with distinct functions that are contextdependent. For instance, SPARC proteolytic derivatives from exogenous MMP3 cleavage
modulate cell proliferation, migration and angiogenesis (Sage et al., 2003) while cleavage
of SPARC in chicken chorioallantoic membrane is associated with pro-angiogenic
properties (Iruela-Arispe et al., 1995). SPARC cleaved by Cathepsin K promotes bone
metastasis (Podgorski et al., 2009) and limited proteolysis in the SPARC EC domain
increases collagens binding (Sasaki et al., 1997; Sasaki et al., 1998; Sasaki et al., 1999).
Interestingly, most of the proteolytic SPARC functions are associated with tissue
remodeling. In mesenteric adipose tissue of obese mice, we discovered two novel
proteolytic SPARC isoforms. Truncation of SPARC within the extracellular calciumbinding domain III in helix C (PVE–LLA) (Sasaki et al., 1999), generates N-SPARC
fragment (Fig 4-5E). This truncation leads to loss of putative 1 integrin binding site but
retains some collagen-binding residues (R149, N156). Consistent with previous reports of
proteolytic cleavage revealing masked epitopes for collagen on SPARC (Sasaki et al., 1997;
Sasaki et al., 1999), N-SPARC displays increased collagen binding affinity and ability to
block integrin interacting with collagen I and fibronectin, but fails to bind ASC. Proteolytic
cleavage of C-SPARC occurs within domain I of SPARC (IVE-EET) and does not affect
its binding to ASC, however, results in decreased interaction of C-SPARC to collagens and
fibronectin. As no known ECM-interacting sites have been reported in the N-terminus of
SPARC, this unanticipated reduction with ECM proteins is likely due to structural changes
of SPARC induced by proteolytic cleavage.
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Our data demonstrate that FL-SPARC and both proteolytic isoforms induce cell deadhesion by acting through distinct mechanisms. Interestingly, despite the loss of its
capacity to bind ASC through 1 integrin, N-SPARC elicits alterations in integrinmediated signaling pathway comparable to those induced by FL-SPARC and C-SPARC.
These data suggest that integrin-FAK-MAPK signaling is modulated by integrindisengagement in cell de-adhesion rather than only by SPARC acting as a ligand. Similarly,
ILK-Akt signaling well known for a role in regulating cell survival is also activated by all
SPARC isoforms. This could be a compensatory mechanism trigger by cell de-adhesion to
avoid anoikis in mobilized cells.
Our study shows that N-SPARC and C-SPARC are generated in the MS WAT of
obese mice and display an additive effect in promoting ASC migration. Building upon our
experimental results and the previously recognized function of SPARC in tissue
remodeling, we propose a model converging functions of SPARC isoforms in tissue
expansion. In WAT of lean mice, basal level of SPARC is expressed by adipocyte,
allowing firm binding of ASC to the perivascular matrix and basement membrane via
integrin 51, therefore, retaining ASC in their niche. In obesity, adipose tissue undergoes
expansion. The increased of SPARC expression and its targeting protease in MS WAT
leads to C-SPARC and N-SPARC accumulation. FL-SPARC, N-SPARC and C-SPARC
promote ASC detachment, by exerting coordinated effect to disrupt α5β1 integrin
engagement with the ECM. FL-SPARC and C-SPARC bind directly to integrin α5β1,
while N-SPARC interacts with ECM to block integrin/ ECM interaction. Detached ASC
migrate and integrate into expanding neovasculature, facilitating WAT expansion. We
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propose that a similar mechanism is accountable for ASC mobilization and underlies the
pathophysiological connection between obesity and cancer.
CONCLUSION
Our study demonstrates that the increased adiposity expands ASC pool which
results in higher frequency of ASC in circulation and tumors. The pro-angiogenic functions
of ASC in stimulating tumor vascularization and growth upon ASC recruitment to tumors
explain the function of WAT in obesity and cancer pathophysiology.
Next, we identified SPARC and its obesity -induced proteolytic derivatives as modulators
of ASC mobilization and migration. The fundamental mechanism of ASC mobilization is
believed to be essential in modulating obesity and applies to activation of ASC in tumor
progression. Protease(s) responsible for SPARC proteolytic derivatives in MS WAT
remain to be identified. Our work highlights the importance of proteolytic processing in
regulation of cellular functions.
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Chapter 6
Future Direction

95

In this thesis study, we demonstrate that SPARC is required for ASC mobilization.
And for the first time, obesity-induced proteolytic derivatives of SPARC are identified in
the mesenteric WAT. SPARC proteolytic derivative C-SPARC has cleavage occurring
within domain I, while N-SPARC is proteolytically cleaved at the (PVE–LLA)
extracellular calcium-binding domain III in helix C. Our result shows that C-SPARC
binds to β1 integrin on ASC, while N-SPARC shows a preferential binding to the ECM
and blocks ECM / integrin interaction. Interestingly, both C-SPARC and N-SPARC induce
ASC de-adhesion from the ECM and cooperate in promoting cell migration. Although we
have shown that SPARC and its proteolytic derivatives regulate ASC mobilization, the
proteases cleaving it remains to be identified.
In attempt to identify putative proteases for generating N-SPARC and C-SPARC in MS
WAT, we evaluated the potential protease cleavage site(s) close to the cleavage region of
N-SPARC and C-SPARC. We identify MMP8 and MMP13 recognition sites to correspond
to N-SPARC cleavage region. Consistently, previous studies reported comparable
molecular weight proteolytic fragments generated by MMP13 proteolysis in vitro (Sasaki
et al., 1997; Sasaki et al., 1998; Sasaki et al., 1999). Lastly, upregulation of MMP8,
MMP13 (Chavey et al., 2003) (Belo et al., 2009; Maquoi et al., 2002) and cathepsins B, D,
K and S (Nadler et al., 2000) are reported in obesity. Therefore, we hypothesize that
MMP8 and MMP13 to be potential protease cleaving SPARC in MS WAT. Additional
studies are required to validate our prediction.
The multifactorial functions of SPARC are controversial and have shown to be highly
contextual. SPARC functions as a tumor suppressor or pro-tumorgenic factor depending on
the stage and cancer types. Our result showing that SPARC proteolytic isoforms
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accumulate in mesenteric WAT is particularly intriguing as visceral adiposity is associated
with numerous pathologies including cancer. Therefore, it would be interesting to evaluate
SPARC and its proteolytic derivative roles in modulating cancer progression.
Our pilot study of EO771 breast adenocarcinoma grafted into SPARC-deficient mice
shows reduced tumor growth (Fig. 6-1A,B) in particular obesity. Haematoxylin eosin
staining of tumor grafts reveals increased viable region in obese WT tumor compared to
SPARC-/- and lean WT counterparts (Fig. 6-1C). These data are consistent with our
previous result showing obesity-associated ASC recruitment support tumor cell survival
and growth. Importantly, tumor grafted onto obese SPARC-/- mice fails to confer growth
and survival advantage, consistent with predicted reduced ASC recruitment in the absence
of SPARC. Immunofluorescence analysis of tumor sections revealed a decrease in ASCassociated progenitor and endothelium markers in SPARC-/- tumors compared to WT (Fig.
6-2). This tumor study reinforces the role of SPARC in modulating ASC mobilization and
tumor trafficking. In the future, we aim to delineate the functional role of SPARC isoforms
in ASC trafficking in the context of tumor progression.
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Figure 6-1. Absence of host SPARC is associated with tumor growth deficiency

(A) Representative breast adenocarcinoma E0771 grafts grown in lean wild type or
SPARC-/- mice (n=5/group). (B) Graph shows volume of tumor grafts from lean and obese
wild type or SPARC-/- mice. (C) Haematoxylin eosin staining of tumor grafts from (B)
shows increased viable region in tumor grafted onto obese wild type mice. N: necrotic, V:
viable. Error bars, SEM from 5 mice. P0.05
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Figure 6-2. Decreased vasculature in tumor grown in SPARC-/- mice.

Immunofluorescence analysis of EO771 tumor sections comparing ASC-associated
endothelium (IB+) and progenitor markers (CD34+, -SMA, PDGFR, PDGFR)
expression in tumor viable regions.
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